<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Semin Thromb Hemost</journal-id><journal-id journal-id-type="iso-abbrev">Semin Thromb Hemost</journal-id><journal-id journal-id-type="pmc-domain-id">3405</journal-id><journal-id journal-id-type="pmc-domain">thiemesd</journal-id><journal-title-group><journal-title>Seminars in Thrombosis and Hemostasis</journal-title></journal-title-group><issn pub-type="ppub">0094-6176</issn><issn pub-type="epub">1098-9064</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Thieme Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431824</article-id><article-id pub-id-type="pmcid-ver">PMC12431824.1</article-id><article-id pub-id-type="pmcaid">12431824</article-id><article-id pub-id-type="pmcaiid">12431824</article-id><article-id pub-id-type="pmid">40154507</article-id><article-id pub-id-type="doi">10.1055/a-2546-0353</article-id><article-id pub-id-type="publisher-id">STH-25-0061-RA</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group><subject>Review Article</subject></subj-group><series-title>Recent Advances in Thrombosis and Hemostasis&#8212;Part XII</series-title><series-text>Guest Editor: Sam Schulman, MD, PhD</series-text></article-categories><title-group><article-title>Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9669-0007</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="Q">Qingui</given-names></name><degrees>MD, PhD</degrees><xref rid="AF250061ra-1" ref-type="aff">1</xref><xref rid="CO250061ra-1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anijs</surname><given-names initials="RJS">Rayna J.S.</given-names></name><degrees>PhD</degrees><xref rid="AF250061ra-1" ref-type="aff">1</xref><xref rid="AF250061ra-2" ref-type="aff">2</xref><xref rid="AF250061ra-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Verlaan</surname><given-names initials="JPL">Judith P.L.</given-names></name><degrees>MSc</degrees><xref rid="AF250061ra-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5282-5520</contrib-id><name name-style="western"><surname>Scheres</surname><given-names initials="LJJ">Luuk J.J.</given-names></name><degrees>MD, PhD</degrees><xref rid="AF250061ra-1" ref-type="aff">1</xref><xref rid="AF250061ra-4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Klok</surname><given-names initials="FA">Frederikus A.</given-names></name><degrees>MD, PhD</degrees><xref rid="AF250061ra-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cannegieter</surname><given-names initials="SC">Suzanne C.</given-names></name><degrees>MD, PhD</degrees><xref rid="AF250061ra-1" ref-type="aff">1</xref><xref rid="AF250061ra-2" ref-type="aff">2</xref></contrib></contrib-group><aff id="AF250061ra-1"><label>1</label><institution>Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands</institution></aff><aff id="AF250061ra-2"><label>2</label><institution>Department of Medicine, Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands</institution></aff><aff id="AF250061ra-3"><label>3</label><institution>The Knowledge Institute of the Federation of Medical Specialists, Utrecht, The Netherlands</institution></aff><aff id="AF250061ra-4"><label>4</label><institution>Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands</institution></aff><author-notes><corresp id="CO250061ra-1"><bold>Address for correspondence </bold>Qingui Chen, MD, PhD <institution>Department of Clinical Epidemiology, Leiden University Medical Center</institution><addr-line>Leiden, 2333 ZA</addr-line><country>the Netherlands</country><email>q.chen@lumc.nl</email><email>qingui4ch@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>51</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">496821</issue-id><fpage>756</fpage><lpage>767</lpage><history><date date-type="received"><day>09</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (
<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>
)
</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s).</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10-1055-a-2546-0353.pdf"/><abstract><p>Novel antidiabetic drugs, particularly sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have significantly transformed the management landscape for type 2 diabetes mellitus, cardiovascular diseases, and chronic kidney diseases, owing to their well-established cardiorenal protective effects. Given the shared risk factors and comorbidities, it is relevant to consider the potential risk of venous thromboembolism (VTE) in individuals prescribed these novel antidiabetic medications. This literature review aims to summarize currently available evidence on VTE risk associated with novel antidiabetic drugs, including GLP-1 receptor agonists, dipeptidyl-peptidase IV (DPP-4) inhibitors, and SGLT2 inhibitors. Following a comprehensive search on PubMed using relevant keywords and backward reference searching, we identified 25 publications that directly reported on associations between these medications and VTE risk. Findings from these studies, including seven meta-analyses, reveal inconsistent results: some studies suggest that GLP-1 receptor agonists or DPP-4 inhibitors may be associated with increased risk of VTE, whereas SGLT2 inhibitors do not appear to be associated with VTE and may even be a protective factor. A notable limitation of the existing studies is the significant challenge posed by confounding in observational studies, while the randomized controlled trials (RCTs) often concluded with a limited number of VTE events, if it was studied. Furthermore, all identified studies focused on the risk of primary VTE, leaving an important knowledge gap regarding whether these novel antidiabetic drugs may influence the efficacy or safety of anticoagulants used for preventing VTE recurrence. Addressing these gaps presents an important avenue for future research.</p></abstract><kwd-group><title>Keywords</title><kwd>glucagon-like peptide-1 receptor agonists</kwd><kwd>dipeptidyl-peptidase IV inhibitors</kwd><kwd>sodium-glucose transporter 2 inhibitors</kwd><kwd>venous thromboembolism</kwd><kwd>hypoglycemic agents</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
Several new classes of antidiabetic drugs have been approved since 2005,
<xref rid="JR250061ra-1" ref-type="bibr">1</xref>
<xref rid="JR250061ra-2" ref-type="bibr">2</xref>
including glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl-peptidase IV (DPP-4) inhibitors, and sodium-glucose cotransporter 2 (SGLT2) inhibitors. Although these agents were initially approved for glucose control or weight reduction, specifically in patients with type 2 diabetes mellitus (T2DM), over the past decade, the additional cardiovascular and renal protective effects of SGLT2 inhibitors and GLP-1 receptor agonists have become increasingly evident.
<xref rid="JR250061ra-3" ref-type="bibr">3</xref>
<xref rid="JR250061ra-4" ref-type="bibr">4</xref>
<xref rid="JR250061ra-5" ref-type="bibr">5</xref>
<xref rid="JR250061ra-6" ref-type="bibr">6</xref>
Furthermore, these benefits have been validated in patients without T2DM, including those with heart failure, chronic kidney disease, or obesity (with preexisting cardiovascular disease).
<xref rid="JR250061ra-7" ref-type="bibr">7</xref>
<xref rid="JR250061ra-8" ref-type="bibr">8</xref>
<xref rid="JR250061ra-9" ref-type="bibr">9</xref>
These developments have revolutionized the management of T2DM,
<xref rid="JR250061ra-10" ref-type="bibr">10</xref>
<xref rid="JR250061ra-11" ref-type="bibr">11</xref>
cardiovascular diseases,
<xref rid="JR250061ra-12" ref-type="bibr">12</xref>
<xref rid="JR250061ra-13" ref-type="bibr">13</xref>
<xref rid="JR250061ra-14" ref-type="bibr">14</xref>
chronic kidney diseases,
<xref rid="JR250061ra-15" ref-type="bibr">15</xref>
and obesity,
<xref rid="JR250061ra-16" ref-type="bibr">16</xref>
as evidenced by a marked increase in the usage of these medications in recent years.
<xref rid="JR250061ra-17" ref-type="bibr">17</xref>
<xref rid="JR250061ra-18" ref-type="bibr">18</xref>
A similar increase has been observed in the use of DPP-4 inhibitors among T2DM patients,
<xref rid="JR250061ra-19" ref-type="bibr">19</xref>
despite their neutral cardiovascular and renal effects.
<xref rid="JR250061ra-10" ref-type="bibr">10</xref>
</p><p>
Unlike the well-documented effects of these novel antidiabetic drugs on arterial thromboembolic complications, such as ischemic stroke and myocardial infarction,
<xref rid="JR250061ra-20" ref-type="bibr">20</xref>
<xref rid="JR250061ra-21" ref-type="bibr">21</xref>
the potential impact of these agents on the occurrence of venous thromboembolism (VTE) remains unclear. Most of the clinical indications for these drugs, including diabetes,
<xref rid="JR250061ra-22" ref-type="bibr">22</xref>
heart failure,
<xref rid="JR250061ra-23" ref-type="bibr">23</xref>
chronic kidney disease,
<xref rid="JR250061ra-24" ref-type="bibr">24</xref>
and obesity,
<xref rid="JR250061ra-25" ref-type="bibr">25</xref>
are associated with shared risk factors for VTE or may even directly contribute to VTE development, and they are as well as linked to risk factors for VTE recurrence.
<xref rid="JR250061ra-26" ref-type="bibr">26</xref>
<xref rid="JR250061ra-27" ref-type="bibr">27</xref>
<xref rid="JR250061ra-28" ref-type="bibr">28</xref>
<xref rid="JR250061ra-29" ref-type="bibr">29</xref>
These conditions are also highly prevalent among patients with VTE or those at increased risk of VTE. The aim of this review is to summarize the available literature focusing on the risk of VTE in individuals receiving these novel antidiabetic drugs, thereby providing insights for future research directions.
</p><sec><title>Methods</title><p>
We conducted a literature search on PubMed covering publications from inception up to February 5, 2025. The keywords used in the search included GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and VTE. The detailed search strategy is provided in
<xref rid="SM250061ra-1" ref-type="supplementary-material">Appendix A1</xref>
(available in the online version only). No language restrictions were applied. The initial search yielded 46 results, which were subsequently reviewed for inclusion.
</p><table-wrap id="TB250061ra-1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Summary of available evidence</title></caption><table rules="all"><colgroup align="left" span="6"><col align="left" width="10.62%" span="1"/><col align="left" width="10.12%" span="1"/><col align="left" width="9.88%" span="1"/><col align="left" width="17.28%" span="1"/><col align="left" width="21.46%" span="1"/><col align="left" width="30.64%" span="1"/></colgroup><thead><tr><th align="left" valign="bottom" colspan="1" rowspan="1">Study</th><th align="left" valign="bottom" colspan="1" rowspan="1">Publication year</th><th align="left" valign="bottom" colspan="1" rowspan="1">Study period</th><th align="left" valign="bottom" colspan="1" rowspan="1">Study design</th><th align="left" valign="bottom" colspan="1" rowspan="1">Study population</th><th align="left" valign="bottom" colspan="1" rowspan="1">Main findings</th></tr></thead><tbody><tr><td align="left" colspan="6" valign="top" rowspan="1">GLP-1RA</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Yin et al.
<xref rid="JR250061ra-31" ref-type="bibr">31</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2021</td><td align="left" valign="top" colspan="1" rowspan="1">Up to October 2020</td><td align="left" valign="top" colspan="1" rowspan="1">Meta-analysis (21 RCTs?)<break/>GLP-1RA (semaglutide) versus controls</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">Semaglutide significantly increased the risk of DVT (RR 3.66, 1.09&#8211;12.25) but not with PE (RR 0.97, 0.47&#8211;1.99)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Liao et al.
<xref rid="JR250061ra-32" ref-type="bibr">32</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2022</td><td align="left" valign="top" colspan="1" rowspan="1">Up to March 2021</td><td align="left" valign="top" colspan="1" rowspan="1">Meta-analysis (6 RCTs)<break/>GLP-1RA (lixisenatide, albiglutide, liraglutide, semaglutide, dulaglutide) versus placebo</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">GLP-1RA was associated with a higher risk of DVT (RR 2.12, 1.32&#8211;3.40)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Almeida et al.
<xref rid="JR250061ra-33" ref-type="bibr">33</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2024</td><td align="left" valign="top" colspan="1" rowspan="1">Up to November 2023</td><td align="left" valign="top" colspan="1" rowspan="1">Meta-analysis (4 RCTs)<break/>GLP-1RA (liraglutide, semaglutide) versus placebo</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with obesity or overweight</td><td align="left" valign="top" colspan="1" rowspan="1">GLP-1RA was not associated with DVT (RR 0.30, 0.06&#8211;1.40)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Elsabbagh et al.
<xref rid="OR250061ra-44" ref-type="bibr">44</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2024</td><td align="left" valign="top" colspan="1" rowspan="1">2010&#8211;2022</td><td align="left" valign="top" colspan="1" rowspan="1">Cohort study<break/>
GLP-1RA (dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide;
<italic toggle="yes">n</italic>
&#8201;=&#8201;5,010) versus non-users (
<italic toggle="yes">n</italic>
&#8201;=&#8201;18,701)
</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients undergoing total shoulder arthroplasty</td><td align="left" valign="top" colspan="1" rowspan="1">No significant increase in 90-day major complications, including DVT (OR 1.27, 0.82&#8211;1.91) and PE (OR 0.70, 0.40&#8211;1.26)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Seddio et al.
<xref rid="JR250061ra-45" ref-type="bibr">45</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2024</td><td align="left" valign="top" colspan="1" rowspan="1">2010&#8211;2022</td><td align="left" valign="top" colspan="1" rowspan="1">Cohort study<break/>
GLP-1RA (semaglutide,
<italic toggle="yes">n</italic>
&#8201;=&#8201;1,094) versus non-users (
<italic toggle="yes">n</italic>
&#8201;=&#8201;4,110)
</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients undergoing primary arthroscopic rotator cuff repair</td><td align="left" valign="top" colspan="1" rowspan="1">Semaglutide was associated with a lower risk of VTE within 90 days after the surgery (OR 3.10, 1.85&#8211;5.64; non-users vs. semaglutide)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Wang et al.
<xref rid="JR250061ra-34" ref-type="bibr">34</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2024</td><td align="left" valign="top" colspan="1" rowspan="1">Up to August 2023</td><td align="left" valign="top" colspan="1" rowspan="1">Meta-analysis (11 RCTs)<break/>GLP-1RA (efpeglenatide, lixisenatide, albiglutide, liraglutide, semaglutide, dulaglutide, tirzepatide) versus controls</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">GLP-1RA was associated with a higher risk of DVT (RR 1.92, 1.23&#8211;3.00)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Lawand et al.
<xref rid="JR250061ra-46" ref-type="bibr">46</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2024</td><td align="left" valign="top" colspan="1" rowspan="1">2012&#8211;2023</td><td align="left" valign="top" colspan="1" rowspan="1">Cohort study<break/>
GLP-1RA (semaglutide or liraglutide,
<italic toggle="yes">n</italic>
&#8201;=&#8201;1,259) versus non-users (
<italic toggle="yes">n</italic>
&#8201;=&#8201;1,259)
</td><td align="left" valign="top" colspan="1" rowspan="1">Patients undergoing primary total shoulder arthroplasty</td><td align="left" valign="top" colspan="1" rowspan="1">GLP-1RA was associated with a higher risk of DVT within 90 days after the surgery (OR 3.0, 1.5&#8211;5.9) but not with PE (OR 1.6, 0.9&#8211;3.1)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Kim et al.
<xref rid="JR250061ra-47" ref-type="bibr">47</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2024</td><td align="left" valign="top" colspan="1" rowspan="1">2010&#8211;2022</td><td align="left" valign="top" colspan="1" rowspan="1">Cohort study<break/>
GLP-1RA (exenatide, semaglutide, dulaglutide, or liraglutide,
<italic toggle="yes">n</italic>
&#8201;=&#8201;2,975) versus non-users (
<italic toggle="yes">n</italic>
&#8201;=&#8201;2,975)
</td><td align="left" valign="top" colspan="1" rowspan="1">Morbidly obese patients undergoing primary total knee arthroplasty</td><td align="left" valign="top" colspan="1" rowspan="1">
GLP-1RA was not associated with DVT within 90 days after the surgery (1.0% vs. 1.1%) but a lower risk of PE (&lt;0.4% vs. 0.6%,
<italic toggle="yes">p</italic>
&#8201;=&#8201;0.050)
</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">DPP-4i</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Arnaud et al.
<xref rid="JR250061ra-41" ref-type="bibr">41</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2017</td><td align="left" valign="top" colspan="1" rowspan="1">2005&#8211;2015</td><td align="left" valign="top" colspan="1" rowspan="1">An automated system combining safety signal detection and prioritization from health care databases</td><td align="left" valign="top" colspan="1" rowspan="1">A French health care database</td><td align="left" valign="top" colspan="1" rowspan="1">There was a strong new signal with DPP-4i and VTE</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Gouverneur et al.
<xref rid="JR250061ra-42" ref-type="bibr">42</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2020</td><td align="left" valign="top" colspan="1" rowspan="1">October 2006&#8211;December 2019</td><td align="left" valign="top" colspan="1" rowspan="1">Disproportionality analyses</td><td align="left" valign="top" colspan="1" rowspan="1">WHO global database of spontaneous reporting adverse drug reactions</td><td align="left" valign="top" colspan="1" rowspan="1">There was an excess of reporting of VTE with DPP-4i compared with other non-insulin glucose-lowering drugs, but only for sitagliptin</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Lu et al.
<xref rid="JR250061ra-43" ref-type="bibr">43</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2020</td><td align="left" valign="top" colspan="1" rowspan="1">2004&#8211;2018</td><td align="left" valign="top" colspan="1" rowspan="1">Disproportionality analyses<break/>DPP-4i versus other glucose-lowering drugs, including SGLT2i</td><td align="left" valign="top" colspan="1" rowspan="1">FDA adverse event reporting system</td><td align="left" valign="top" colspan="1" rowspan="1">No association between DPP-4i and VTE<break/>Moderate to strong signals of portal vein thrombosis, splenic vein thrombosis, and mesenteric vein thrombosis risks</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Xin et al.
<xref rid="JR250061ra-35" ref-type="bibr">35</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2021</td><td align="left" valign="top" colspan="1" rowspan="1">Up to May 2020</td><td align="left" valign="top" colspan="1" rowspan="1">Meta-analysis (5 RCTs)<break/>DPP-4i (saxagliptin, alogliptin, sitagliptin, omarigliptin, linagliptin) versus placebo</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">DPP-4i was not associated with VTE (OR 1.12, 0.81&#8211;1.55) or PE (OR 1.14, 0.68&#8211;1.90)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Deischinger et al.
<xref rid="JR250061ra-48" ref-type="bibr">48</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2022</td><td align="left" valign="top" colspan="1" rowspan="1">1997&#8211;2014</td><td align="left" valign="top" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">
DPP-4i was associated with VTE in female T2DM patients (OR 2.3,
<italic toggle="yes">p</italic>
&#8201;=&#8201;0.0096) but not among males (OR 1.6,
<italic toggle="yes">p</italic>
&#8201;=&#8201;0.28)
</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Liao et al.
<xref rid="JR250061ra-32" ref-type="bibr">32</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2022</td><td align="left" valign="top" colspan="1" rowspan="1">Up to March 2021</td><td align="left" valign="top" colspan="1" rowspan="1">Meta-analysis (5 RCTs)<break/>DPP-4i (linagliptin, alogliptin, omarigliptin, saxagliptin, sitagliptin) versus placebo</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">DPP-4i was not associated with DVT (RR 0.92, 0.54&#8211;1.57)</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">SGLT2i</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Wang et al.
<xref rid="JR250061ra-36" ref-type="bibr">36</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2019</td><td align="left" valign="top" colspan="1" rowspan="1">Up to April 2019</td><td align="left" valign="top" colspan="1" rowspan="1">Meta-analysis (29 RCTs)<break/>SGLT2i (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) versus controls</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">SGLT2i was not associated with VTE (RR 0.98, 0.75&#8211;1.28), DVT (RR 1.06, 0.60&#8211;1.89), or PE (0.99, 0.67&#8211;1.46).</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Patel et al.
<xref rid="JR250061ra-38" ref-type="bibr">38</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2020</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">Pooled analysis (7 RCTs)<break/>SGLT2i (ertugliflozin) versus controls</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">SGLT2i was not associated with VTE</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Liao et al.
<xref rid="JR250061ra-32" ref-type="bibr">32</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2022</td><td align="left" valign="top" colspan="1" rowspan="1">Up to March 2021</td><td align="left" valign="top" colspan="1" rowspan="1">Meta-analysis (9 RCTs)<break/>SGLT2i (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) versus placebo</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with T2DM (6 RCTs), heart failure (2 RCTs), or chronic kidney disease (1 RCT)</td><td align="left" valign="top" colspan="1" rowspan="1">SGLT2i was not associated with DVT (RR 1.03, 0.69&#8211;1.53)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
St&#246;llberger et al.
<xref rid="JR250061ra-39" ref-type="bibr">39</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2023</td><td align="left" valign="top" colspan="1" rowspan="1">&#8211;</td><td align="left" valign="top" colspan="1" rowspan="1">Systematic review</td><td align="left" valign="top" colspan="1" rowspan="1">Congestive heart failure patients</td><td align="left" valign="top" colspan="1" rowspan="1">
Only two trials
<xref rid="JR250061ra-121" ref-type="bibr">121</xref>
<xref rid="JR250061ra-130" ref-type="bibr">130</xref>
reported VTE as adverse events, but the incidence was low and did not differ between SGLT2i and placebo
</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Wang et al.
<xref rid="JR250061ra-34" ref-type="bibr">34</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2024</td><td align="left" valign="top" colspan="1" rowspan="1">Up to August 2023</td><td align="left" valign="top" colspan="1" rowspan="1">Meta-analysis (14 RCTs)<break/>SGLT2i (canagliflozin, dapagliflozin, empagliflozin, sotagliflozin) versus placebo</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with T2DM, heart failure, or chronic kidney disease</td><td align="left" valign="top" colspan="1" rowspan="1">SGLT2i was not associated with DVT (RR 0.80, 0.58&#8211;1.11)</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">SGLT2i versus GLP-1RA</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Ueda et al.
<xref rid="JR250061ra-49" ref-type="bibr">49</xref>
<break/>
(Caparrotta et al.
<xref rid="JR250061ra-40" ref-type="bibr">40</xref>
)
<xref rid="FN250061ra-2" ref-type="table-fn">a</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2018<break/>(2021)</td><td align="left" valign="top" colspan="1" rowspan="1">July 2013&#8211;December 2016</td><td align="left" valign="top" colspan="1" rowspan="1">Cohort study<break/>(systematic review)<break/>
SGLT2i (dapagliflozin, empagliflozin, canagliflozin,
<italic toggle="yes">n</italic>
&#8201;=&#8201;17,213) versus GLP-1RA (liraglutide?
<italic toggle="yes">n</italic>
&#8201;=&#8201;17,213)
</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">No difference in VTE (HR 0.99, 0.71&#8211;1.38)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Patil et al.
<xref rid="JR250061ra-50" ref-type="bibr">50</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2023</td><td align="left" valign="top" colspan="1" rowspan="1">April 2013&#8211;September 2020</td><td align="left" valign="top" colspan="1" rowspan="1">Cohort study<break/>
SGLT2i (empagliflozin, canagliflozin, dapagliflozin;
<italic toggle="yes">n</italic>
&#8201;=&#8201;35,347) versus GLP-1RA (liraglutide, dulaglutide, lixisenatide, orsemaglutide;
<italic toggle="yes">n</italic>
&#8201;=&#8201;35,347)
</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">SGLT2i was not associated with VTE (HR 1.02, 0.80&#8211;1.30)</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">SGLT2i versus DPP-4i</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Schmedt et al.
<xref rid="JR250061ra-51" ref-type="bibr">51</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2021</td><td align="left" valign="top" colspan="1" rowspan="1">2012&#8211;2018</td><td align="left" valign="top" colspan="1" rowspan="1">Case&#8211;control study?<break/>
SGLT2i (
<italic toggle="yes">n</italic>
&#8201;=&#8201;4,705) versus DPP-4i (
<italic toggle="yes">n</italic>
&#8201;=&#8201;14,840)
</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">SGLT2i was associated with a lower VTE risk (RR 0.75, 0.59&#8211;0.94) for both dapagliflozin and empagliflozin</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Aloe et al.
<xref rid="JR250061ra-52" ref-type="bibr">52</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2023</td><td align="left" valign="top" colspan="1" rowspan="1">2013&#8211;2017</td><td align="left" valign="top" colspan="1" rowspan="1">Cohort study<break/>
SGLT2i (
<italic toggle="yes">n</italic>
&#8201;=&#8201;5,414) versus DPP-4i (
<italic toggle="yes">n</italic>
&#8201;=&#8201;5,414)
</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">SGLT2i was not associated with VTE (HR 0.65, 0.34&#8211;1.25) among both prevalent and incident users</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">
Tsai et al.
<xref rid="JR250061ra-53" ref-type="bibr">53</xref>
</td><td align="left" valign="top" colspan="1" rowspan="1">2024</td><td align="left" valign="top" colspan="1" rowspan="1">May 2016&#8211;December 2020</td><td align="left" valign="top" colspan="1" rowspan="1">Cohort study<break/>
SGLT2i (
<italic toggle="yes">n</italic>
&#8201;=&#8201;123,567) versus DPP4-i (
<italic toggle="yes">n</italic>
&#8201;=&#8201;578,665)
</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">SGLT2i was associated with a lower risk of retinal vein occlusion (HR 0.76, 0.59&#8211;0.98), but for branch retinal vein occlusion only</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">DPP-4i, SGLT2i, and GLP-1RA</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">
Tsai et al.
<xref rid="JR250061ra-37" ref-type="bibr">37</xref>
</td><td align="left" rowspan="2" valign="top" colspan="1">2024</td><td align="left" valign="top" colspan="1" rowspan="1">May 2016&#8211;December 2020</td><td align="left" valign="top" colspan="1" rowspan="1">Cohort study<break/>
DPP-4i (
<italic toggle="yes">n</italic>
&#8201;=&#8201;598,280), SGLT2i (
<italic toggle="yes">n</italic>
&#8201;=&#8201;136,530), versus GLP-1RA (
<italic toggle="yes">n</italic>
&#8201;=&#8201;5,760)
</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">SGLT2i versus DPP-4i was associated with a lower VTE risk (HR 0.70, 0.59&#8211;0.84) but not with GLP-1RA (HR 1.39, 0.32&#8211;5.94)</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Up to May 2023</td><td align="left" valign="top" colspan="1" rowspan="1">Meta-analysis (3 observational studies)</td><td align="left" valign="top" colspan="1" rowspan="1">T2DM patients</td><td align="left" valign="top" colspan="1" rowspan="1">SGLT2i versus DPP-4i: lower VTE risk (HR 0.71, 0.62&#8211;0.82); SGLT2i versus GLP-1RA: no association (HR 0.91, 0.73&#8211;1.15)</td></tr></tbody></table><table-wrap-foot><fn id="FN250061ra-1"><p>Abbreviations: DPP-4i, dipeptidyl-peptidase IV inhibitor; DVT, deep vein thrombosis; FDA, Food and Drug Administration; GLP-1RA, glucagon-like peptide-1 receptor agonist; HR, hazard ratio; OR, odds ratio; PE, pulmonary embolism; RCT, randomized controlled trial; RR, risk ratio; SGLT2i, sodium-glucose transporter 2 inhibitor; T2DM, type 2 diabetes mellitus; VTE, venous thromboembolism; WHO, World Health Organization.</p></fn><fn id="FN250061ra-2"><label>a</label><p>
A systematic review referring to the study by Ueda et al.
<xref rid="JR250061ra-49" ref-type="bibr">49</xref>
</p></fn></table-wrap-foot></table-wrap><p>
The primary inclusion criterion was human studies, encompassing observational studies, RCTs (or secondary analyses of RCTs), and meta-analyses that reported on the risk of VTE, including deep vein thrombosis (DVT), pulmonary embolism (PE), or both, in patients receiving one of the three classes of novel antidiabetic drugs compared with those receiving placebos or other antidiabetic drugs (including other classes of novel antidiabetic drugs). Studies that assessed associations between novel antidiabetic drugs and VTE using methods such as disproportionality analyses
<xref rid="JR250061ra-30" ref-type="bibr">30</xref>
were also included. General reviews, case reports, comments, or fundamental research were generally excluded; however, given the limited number of relevant publications, the full text of all identified publications was reviewed, and specific sections were carefully examined where appropriate and necessary. Additionally, relevant studies identified through reference lists of included publications were considered for inclusion. Since RCTs on novel antidiabetic drugs often included VTE as a safety outcome but ultimately observed very few events, we did not further review details of these RCTs (unless they were captured in our literature search). Instead, meta-analyses of these RCTs (if any) were reviewed.
</p><p>For each identified study, we extracted information such as publication year, study period, study design, study population, and main findings. Information from other publications relevant to the review topic, such as potential mechanisms underlying the associations between novel antidiabetic drugs and VTE, may be mentioned in the discussion, though these references are not exhaustive.</p></sec><sec><title>Results</title><p>
As shown in
<xref rid="TB250061ra-1" ref-type="table">Table 1</xref>
, 25 studies (including 1 identified through backward reference searching) were ultimately included. These comprised 7 meta-analyses,
<xref rid="JR250061ra-31" ref-type="bibr">31</xref>
<xref rid="JR250061ra-32" ref-type="bibr">32</xref>
<xref rid="JR250061ra-33" ref-type="bibr">33</xref>
<xref rid="JR250061ra-34" ref-type="bibr">34</xref>
<xref rid="JR250061ra-35" ref-type="bibr">35</xref>
<xref rid="JR250061ra-36" ref-type="bibr">36</xref>
<xref rid="JR250061ra-37" ref-type="bibr">37</xref>
1 pooled analysis of RCTs,
<xref rid="JR250061ra-38" ref-type="bibr">38</xref>
2 systematic reviews,
<xref rid="JR250061ra-39" ref-type="bibr">39</xref>
<xref rid="JR250061ra-40" ref-type="bibr">40</xref>
and 3 disproportionality analyses,
<xref rid="JR250061ra-41" ref-type="bibr">41</xref>
<xref rid="JR250061ra-42" ref-type="bibr">42</xref>
<xref rid="JR250061ra-43" ref-type="bibr">43</xref>
in addition to 11 traditional observational studies.
<xref rid="JR250061ra-37" ref-type="bibr">37</xref>
<xref rid="OR250061ra-44" ref-type="bibr">44</xref>
<xref rid="JR250061ra-45" ref-type="bibr">45</xref>
<xref rid="JR250061ra-46" ref-type="bibr">46</xref>
<xref rid="JR250061ra-47" ref-type="bibr">47</xref>
<xref rid="JR250061ra-48" ref-type="bibr">48</xref>
<xref rid="JR250061ra-49" ref-type="bibr">49</xref>
<xref rid="JR250061ra-50" ref-type="bibr">50</xref>
<xref rid="JR250061ra-51" ref-type="bibr">51</xref>
<xref rid="JR250061ra-52" ref-type="bibr">52</xref>
<xref rid="JR250061ra-53" ref-type="bibr">53</xref>
</p><sec><title>Glucagon-like Peptide-1 Receptor Agonists and Venous Thromboembolism Risk</title><p>
A total of eight studies
<xref rid="JR250061ra-31" ref-type="bibr">31</xref>
<xref rid="JR250061ra-32" ref-type="bibr">32</xref>
<xref rid="JR250061ra-33" ref-type="bibr">33</xref>
<xref rid="JR250061ra-34" ref-type="bibr">34</xref>
<xref rid="OR250061ra-44" ref-type="bibr">44</xref>
<xref rid="JR250061ra-45" ref-type="bibr">45</xref>
<xref rid="JR250061ra-46" ref-type="bibr">46</xref>
<xref rid="JR250061ra-47" ref-type="bibr">47</xref>
were identified that compared VTE risks between individuals receiving GLP-1 receptor agonists and those not receiving these agents, with inconsistent results reported. A meta-analysis by Yin et al.
<xref rid="JR250061ra-31" ref-type="bibr">31</xref>
included 21 RCTs (i.e., the PIONEER
<xref rid="JR250061ra-54" ref-type="bibr">54</xref>
<xref rid="JR250061ra-55" ref-type="bibr">55</xref>
<xref rid="JR250061ra-56" ref-type="bibr">56</xref>
<xref rid="JR250061ra-57" ref-type="bibr">57</xref>
<xref rid="JR250061ra-58" ref-type="bibr">58</xref>
<xref rid="JR250061ra-59" ref-type="bibr">59</xref>
<xref rid="JR250061ra-60" ref-type="bibr">60</xref>
<xref rid="JR250061ra-61" ref-type="bibr">61</xref>
<xref rid="JR250061ra-62" ref-type="bibr">62</xref>
<xref rid="JR250061ra-63" ref-type="bibr">63</xref>
and SUSTAIN trials
<xref rid="JR250061ra-64" ref-type="bibr">64</xref>
<xref rid="JR250061ra-65" ref-type="bibr">65</xref>
<xref rid="JR250061ra-66" ref-type="bibr">66</xref>
<xref rid="JR250061ra-67" ref-type="bibr">67</xref>
<xref rid="JR250061ra-68" ref-type="bibr">68</xref>
<xref rid="JR250061ra-69" ref-type="bibr">69</xref>
<xref rid="JR250061ra-70" ref-type="bibr">70</xref>
<xref rid="JR250061ra-71" ref-type="bibr">71</xref>
<xref rid="JR250061ra-72" ref-type="bibr">72</xref>
<xref rid="JR250061ra-73" ref-type="bibr">73</xref>
<xref rid="JR250061ra-74" ref-type="bibr">74</xref>
) designed to evaluate the efficacy of semaglutide in T2DM patients. Among the various investigated safety outcomes, semaglutide was associated with an increased risk of DVT (8/5,844 vs. 1/7,495; risk ratio [RR] 3.66, 95% confidence interval [CI] 1.09&#8211;12.25) but not with PE (11/5,303 vs. 19/7,565; RR 0.97, 95% CI 0.47&#8211;1.99). However, the trials included for the analyses of DVT or PE are not reported. Another meta-analysis by Liao et al.,
<xref rid="JR250061ra-32" ref-type="bibr">32</xref>
which included six RCTs involving T2DM patients,
<xref rid="JR250061ra-5" ref-type="bibr">5</xref>
<xref rid="JR250061ra-55" ref-type="bibr">55</xref>
<xref rid="JR250061ra-64" ref-type="bibr">64</xref>
<xref rid="JR250061ra-75" ref-type="bibr">75</xref>
<xref rid="JR250061ra-76" ref-type="bibr">76</xref>
<xref rid="JR250061ra-77" ref-type="bibr">77</xref>
consistently found that GLP-1 receptor agonists (various subtypes vs. placebo) were associated with an increased risk of DVT (55/20,598 vs. 25/20,608; RR 2.12, 95% CI 1.32&#8211;3.40). Wang et al.
<xref rid="JR250061ra-34" ref-type="bibr">34</xref>
conducted a meta-analysis including 11 RCTs involving T2DM patients
<xref rid="JR250061ra-5" ref-type="bibr">5</xref>
<xref rid="JR250061ra-54" ref-type="bibr">54</xref>
<xref rid="JR250061ra-55" ref-type="bibr">55</xref>
<xref rid="JR250061ra-64" ref-type="bibr">64</xref>
<xref rid="JR250061ra-67" ref-type="bibr">67</xref>
<xref rid="JR250061ra-75" ref-type="bibr">75</xref>
<xref rid="JR250061ra-76" ref-type="bibr">76</xref>
<xref rid="JR250061ra-77" ref-type="bibr">77</xref>
<xref rid="JR250061ra-78" ref-type="bibr">78</xref>
<xref rid="JR250061ra-79" ref-type="bibr">79</xref>
<xref rid="JR250061ra-80" ref-type="bibr">80</xref>
(various subtypes, mostly with placebo as the control arm, but also including two trials using DPP-4 inhibitors and one using insulin) and similarly reported an increased DVT risk (62/29,005 vs. 28/25,078; RR 1.92, 95% CI 1.23&#8211;3.00). In contrast, another meta-analysis
<xref rid="JR250061ra-33" ref-type="bibr">33</xref>
found no association between GLP-1 receptor agonists (including liraglutide and semaglutide) and DVT risk (2/5,015 vs. 3/2,237; RR 0.30, 95% CI 0.06&#8211;1.40), although this study focused on patients with obesity or overweight conditions.
<xref rid="JR250061ra-81" ref-type="bibr">81</xref>
<xref rid="JR250061ra-82" ref-type="bibr">82</xref>
<xref rid="JR250061ra-83" ref-type="bibr">83</xref>
<xref rid="JR250061ra-84" ref-type="bibr">84</xref>
</p><p>
Additionally, four cohort studies examined postoperative VTE risk in T2DM or morbidly obese patients receiving GLP-1 receptor agonists.
<xref rid="OR250061ra-44" ref-type="bibr">44</xref>
<xref rid="JR250061ra-45" ref-type="bibr">45</xref>
<xref rid="JR250061ra-46" ref-type="bibr">46</xref>
<xref rid="JR250061ra-47" ref-type="bibr">47</xref>
The study by Elsabbagh et al.
<xref rid="OR250061ra-44" ref-type="bibr">44</xref>
investigated DVT or PE risk within 90 days after total shoulder arthroplasty and found no significant difference in DVT risk (odds ratio [OR] 1.27, 95% CI 0.82&#8211;1.91) or PE risk (OR 0.70, 95% CI 0.40&#8211;1.26) between GLP-1 receptor agonist users and non-users. Conversely, Lawand et al.
<xref rid="JR250061ra-46" ref-type="bibr">46</xref>
found those who received GLP-1 receptor agonists after the same procedure had a significantly higher DVT risk (OR 3.0, 95% CI 1.5&#8211;5.9), although there was no significant difference in PE risk (OR 1.6, 95% CI 0.9&#8211;3.1). The studies by Seddio et al.
<xref rid="JR250061ra-45" ref-type="bibr">45</xref>
and Kim et al.
<xref rid="JR250061ra-47" ref-type="bibr">47</xref>
examined VTE risk after two other procedures (i.e., arthroscopic rotator cuff repair and total knee arthroplasty), and both found GLP-1 receptor agonists were a protective factor against VTE (or PE) within 90 days after the procedures. These observational studies often employed matching methods (propensity-score matching or exact matching) to control for confounding factors. Only the study by Kim et al.
<xref rid="JR250061ra-47" ref-type="bibr">47</xref>
clearly reported postoperative prophylactic anticoagulation, which might not be routinely provided in the other three studies
<xref rid="OR250061ra-44" ref-type="bibr">44</xref>
<xref rid="JR250061ra-45" ref-type="bibr">45</xref>
<xref rid="JR250061ra-46" ref-type="bibr">46</xref>
(according to the types of procedure).
</p></sec><sec><title>Dipeptidyl-peptidase-IV Inhibitors and Venous Thromboembolism Risk</title><p>
A total of six studies
<xref rid="JR250061ra-32" ref-type="bibr">32</xref>
<xref rid="JR250061ra-35" ref-type="bibr">35</xref>
<xref rid="JR250061ra-41" ref-type="bibr">41</xref>
<xref rid="JR250061ra-42" ref-type="bibr">42</xref>
<xref rid="JR250061ra-43" ref-type="bibr">43</xref>
<xref rid="JR250061ra-48" ref-type="bibr">48</xref>
examined the association between DPP-4 inhibitors and VTE risk. Three of these studies used public health care data to detect drug safety signals, with two identifying a VTE safety signal associated with DPP-4 inhibitors,
<xref rid="JR250061ra-41" ref-type="bibr">41</xref>
<xref rid="JR250061ra-42" ref-type="bibr">42</xref>
while one did not find such an association.
<xref rid="JR250061ra-43" ref-type="bibr">43</xref>
In detail, Arnaud et al.
<xref rid="JR250061ra-41" ref-type="bibr">41</xref>
analyzed data from a French health care database and found safety signals indicating associations between PE and vidagliptin, PE and saxagliptin, and VTE and sitagliptin. Gouverneur et al.
<xref rid="JR250061ra-42" ref-type="bibr">42</xref>
used the World Health Organization global database of individual case safety reports of potential adverse drug reactions and performed disproportionality analyses, finding an excess of VTE reports associated with DPP-4 inhibitors compared with other non-insulin glucose-lowering drugs, though the excess risk appeared to be limited to sitagliptin users based on a post hoc subgroup analysis. However, Lu et al.,
<xref rid="JR250061ra-43" ref-type="bibr">43</xref>
using data from spontaneous reporting systems of drug adverse events, conducted disproportionality analyses and found no signal of an association between DPP-4 inhibitors and VTE risk, though there were moderate to strong signals for risks of portal vein thrombosis, splenic vein thrombosis, and mesenteric vein thrombosis.
</p><p>
Two meta-analyses
<xref rid="JR250061ra-32" ref-type="bibr">32</xref>
<xref rid="JR250061ra-35" ref-type="bibr">35</xref>
consistently reported no association between DPP-4 inhibitors and VTE in T2DM patients. The meta-analysis by Xin et al.,
<xref rid="JR250061ra-35" ref-type="bibr">35</xref>
which included five cardiovascular outcomes trials,
<xref rid="JR250061ra-85" ref-type="bibr">85</xref>
<xref rid="JR250061ra-86" ref-type="bibr">86</xref>
<xref rid="JR250061ra-87" ref-type="bibr">87</xref>
<xref rid="JR250061ra-88" ref-type="bibr">88</xref>
<xref rid="JR250061ra-89" ref-type="bibr">89</xref>
found no association between DPP-4 inhibitors (various subtypes vs. placebo) and VTE (79/23,899 vs. 70/23,815; OR 1.12, 95% CI 0.81&#8211;1.55) or PE (31/23,899 vs. 27/23,815; OR 1.14, 95% CI 0.68&#8211;1.90). Similarly, Liao et al.
<xref rid="JR250061ra-32" ref-type="bibr">32</xref>
included five RCTs
<xref rid="JR250061ra-85" ref-type="bibr">85</xref>
<xref rid="JR250061ra-86" ref-type="bibr">86</xref>
<xref rid="JR250061ra-87" ref-type="bibr">87</xref>
<xref rid="JR250061ra-88" ref-type="bibr">88</xref>
<xref rid="JR250061ra-89" ref-type="bibr">89</xref>
and found no association with DVT risk (26/23,833 vs. 28/23,750; RR 0.92, 95% CI 0.54&#8211;1.57). In contrast, a case&#8211;control study reported that DPP-4 inhibitors were associated with increased VTE risk in female T2DM patients only (OR 2.3,
<italic toggle="yes">p</italic>
&#8201;=&#8201;0.0096).
<xref rid="JR250061ra-48" ref-type="bibr">48</xref>
However, details regarding confounding control were not clearly provided, as this was an additional analysis within the study.
</p></sec><sec><title>Sodium-Glucose Cotransporter 2 Inhibitors and Venous Thromboembolism Risk</title><p>
Five studies examined VTE risk in patients receiving SGLT2 inhibitors, including three meta-analyses,
<xref rid="JR250061ra-32" ref-type="bibr">32</xref>
<xref rid="JR250061ra-34" ref-type="bibr">34</xref>
<xref rid="JR250061ra-36" ref-type="bibr">36</xref>
a pooled analysis of RCTs,
<xref rid="JR250061ra-38" ref-type="bibr">38</xref>
and a systematic review.
<xref rid="JR250061ra-39" ref-type="bibr">39</xref>
These studies consistently reported no association between SGLT2 inhibitors and VTE or DVT. Wang et al.
<xref rid="JR250061ra-36" ref-type="bibr">36</xref>
performed a meta-analysis of 29 RCTs
<xref rid="JR250061ra-3" ref-type="bibr">3</xref>
<xref rid="JR250061ra-90" ref-type="bibr">90</xref>
<xref rid="JR250061ra-91" ref-type="bibr">91</xref>
<xref rid="JR250061ra-92" ref-type="bibr">92</xref>
<xref rid="JR250061ra-93" ref-type="bibr">93</xref>
<xref rid="JR250061ra-94" ref-type="bibr">94</xref>
<xref rid="JR250061ra-95" ref-type="bibr">95</xref>
<xref rid="JR250061ra-96" ref-type="bibr">96</xref>
<xref rid="JR250061ra-97" ref-type="bibr">97</xref>
<xref rid="JR250061ra-98" ref-type="bibr">98</xref>
<xref rid="JR250061ra-99" ref-type="bibr">99</xref>
<xref rid="JR250061ra-100" ref-type="bibr">100</xref>
<xref rid="JR250061ra-101" ref-type="bibr">101</xref>
<xref rid="JR250061ra-102" ref-type="bibr">102</xref>
<xref rid="JR250061ra-103" ref-type="bibr">103</xref>
<xref rid="JR250061ra-104" ref-type="bibr">104</xref>
<xref rid="JR250061ra-105" ref-type="bibr">105</xref>
<xref rid="JR250061ra-106" ref-type="bibr">106</xref>
<xref rid="JR250061ra-107" ref-type="bibr">107</xref>
<xref rid="JR250061ra-108" ref-type="bibr">108</xref>
<xref rid="JR250061ra-109" ref-type="bibr">109</xref>
<xref rid="JR250061ra-110" ref-type="bibr">110</xref>
<xref rid="JR250061ra-111" ref-type="bibr">111</xref>
<xref rid="JR250061ra-112" ref-type="bibr">112</xref>
<xref rid="JR250061ra-113" ref-type="bibr">113</xref>
<xref rid="JR250061ra-114" ref-type="bibr">114</xref>
<xref rid="JR250061ra-115" ref-type="bibr">115</xref>
<xref rid="JR250061ra-116" ref-type="bibr">116</xref>
<xref rid="JR250061ra-117" ref-type="bibr">117</xref>
and found no significant difference in VTE risk between T2DM patients receiving SGLT2 inhibitors and those who did not (128/32,038 vs. 92/23,997; RR 0.98, 95% CI 0.75&#8211;1.28), with consistent results for DVT and PE separately. Most of the control arms in these RCTs were placebo, although some used other antidiabetic drugs, including DPP-4 inhibitors. Liao et al.
<xref rid="JR250061ra-32" ref-type="bibr">32</xref>
included nine RCTs
<xref rid="JR250061ra-3" ref-type="bibr">3</xref>
<xref rid="JR250061ra-7" ref-type="bibr">7</xref>
<xref rid="JR250061ra-8" ref-type="bibr">8</xref>
<xref rid="JR250061ra-113" ref-type="bibr">113</xref>
<xref rid="JR250061ra-115" ref-type="bibr">115</xref>
<xref rid="JR250061ra-117" ref-type="bibr">117</xref>
<xref rid="JR250061ra-118" ref-type="bibr">118</xref>
<xref rid="JR250061ra-119" ref-type="bibr">119</xref>
(note that trials <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01032629">NCT01032629</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01989754">NCT01989754</ext-link> are in one publication
<xref rid="JR250061ra-113" ref-type="bibr">113</xref>
) in their meta-analysis, reporting no association (vs. placebo) between SGLT2 inhibitors and DVT risk (61/33,124 vs. 48/26,568; RR 1.03, 95% CI 0.69&#8211;1.53). Although the majority of the included RCTs involved T2DM patients, two studies included heart failure patients,
<xref rid="JR250061ra-7" ref-type="bibr">7</xref>
<xref rid="JR250061ra-118" ref-type="bibr">118</xref>
and one involved chronic kidney disease patients.
<xref rid="JR250061ra-8" ref-type="bibr">8</xref>
Another meta-analysis by Wang et al.
<xref rid="JR250061ra-34" ref-type="bibr">34</xref>
included 14 RCTs
<xref rid="JR250061ra-3" ref-type="bibr">3</xref>
<xref rid="JR250061ra-7" ref-type="bibr">7</xref>
<xref rid="JR250061ra-8" ref-type="bibr">8</xref>
<xref rid="JR250061ra-113" ref-type="bibr">113</xref>
<xref rid="JR250061ra-115" ref-type="bibr">115</xref>
<xref rid="JR250061ra-117" ref-type="bibr">117</xref>
<xref rid="JR250061ra-118" ref-type="bibr">118</xref>
<xref rid="JR250061ra-119" ref-type="bibr">119</xref>
<xref rid="JR250061ra-120" ref-type="bibr">120</xref>
<xref rid="JR250061ra-121" ref-type="bibr">121</xref>
<xref rid="JR250061ra-122" ref-type="bibr">122</xref>
<xref rid="JR250061ra-123" ref-type="bibr">123</xref>
<xref rid="JR250061ra-124" ref-type="bibr">124</xref>
and similarly found no association between SGLT2 inhibitors (vs. placebo) and DVT risk (80/48,446 vs. 86/41,886; RR 0.80, 95% CI 0.58&#8211;1.11), with trials involving patients with T2DM, heart failure, or chronic kidney disease.
</p><p>
In addition to these three meta-analyses, a pooled analysis
<xref rid="JR250061ra-38" ref-type="bibr">38</xref>
of seven RCTs
<xref rid="JR250061ra-112" ref-type="bibr">112</xref>
<xref rid="JR250061ra-114" ref-type="bibr">114</xref>
<xref rid="JR250061ra-125" ref-type="bibr">125</xref>
<xref rid="JR250061ra-126" ref-type="bibr">126</xref>
<xref rid="JR250061ra-127" ref-type="bibr">127</xref>
<xref rid="JR250061ra-128" ref-type="bibr">128</xref>
<xref rid="JR250061ra-129" ref-type="bibr">129</xref>
reported no association between SGLT2 inhibitors and VTE risk in T2DM patients, though limited details were provided regarding this outcome. A systematic review
<xref rid="JR250061ra-39" ref-type="bibr">39</xref>
identified only two trials
<xref rid="JR250061ra-121" ref-type="bibr">121</xref>
<xref rid="JR250061ra-130" ref-type="bibr">130</xref>
involving heart failure patients that reported VTE as an adverse event, with a low incidence that did not differ between SGLT2 inhibitors and placebo.
</p></sec><sec><title>Venous Thromboembolism Risk among the Three Classes of Novel Antidiabetic Drugs</title><p>
The remaining studies primarily compared VTE risk among the three classes of novel antidiabetic drugs (
<xref rid="TB250061ra-1" ref-type="table">Table 1</xref>
), although no studies were specifically identified that directly compared GLP-1 receptor agonists with DPP-4 inhibitors.
</p><p>
Two cohort studies, both involving T2DM patients, compared patients receiving SGLT2 inhibitors to those receiving GLP-1 receptor agonists and found no difference in VTE risk.
<xref rid="JR250061ra-49" ref-type="bibr">49</xref>
<xref rid="JR250061ra-50" ref-type="bibr">50</xref>
Ueda et al.
<xref rid="JR250061ra-49" ref-type="bibr">49</xref>
utilized nationwide data from Sweden and Denmark, including 17,213 patients on SGLT2 inhibitors and GLP-1 receptor agonists, respectively, with a median follow-up of about 9 months, found no association between SGLT2 inhibitors and VTE (hazard ratio [HR] 0.99, 95% CI 0.71&#8211;1.38; absolute risk difference 0.2, 95% CI &#8722;0.4 to 1.3). Confounding was controlled using an active comparator new-user study design and propensity-score matching. Similarly, Patil et al.
<xref rid="JR250061ra-50" ref-type="bibr">50</xref>
conducted a study using nationwide U.S. data, with an approximately doubled sample size (
<italic toggle="yes">n</italic>
&#8201;=&#8201;35,347) and slightly longer median follow-ups (i.e., 1.01 and 1.54 years, respectively), and reported that SGLT2 inhibitors were not associated with VTE risk (HR 1.02, 95% CI 0.80&#8211;1.30) compared with GLP-1 receptor agonists.
</p><p>
Three observational studies compared VTE risk between SGLT2 inhibitors and DPP-4 inhibitors in T2DM patients.
<xref rid="JR250061ra-51" ref-type="bibr">51</xref>
<xref rid="JR250061ra-52" ref-type="bibr">52</xref>
<xref rid="JR250061ra-53" ref-type="bibr">53</xref>
Schmedt et al.
<xref rid="JR250061ra-51" ref-type="bibr">51</xref>
used a nested case&#8211;control design to include 2,152 VTE cases and 85,104 matched controls, finding that SGLT2 inhibitors were associated with a lower VTE risk compared with DPP-4 inhibitors (RR 0.75, 95% CI 0.59&#8211;0.94, though the estimate may actually represent OR based on the described methodology). This association was consistently observed by subtypes of SGLT2 inhibitors (i.e., dapagliflozin or empagliflozin). Similar results were observed in a cohort study,
<xref rid="JR250061ra-53" ref-type="bibr">53</xref>
which found that SGLT2 inhibitors were associated with a reduced risk of retinal vein occlusion compared with DPP-4 inhibitors (HR 0.76, 95% CI 0.59&#8211;0.98), though this association was only observed for branch retinal vein occlusion and not central retinal vein occlusion. Conversely, Aloe et al.
<xref rid="JR250061ra-52" ref-type="bibr">52</xref>
found no significant reduction in VTE risk with SGLT2 inhibitors compared with DPP-4 inhibitors (
<italic toggle="yes">n</italic>
&#8201;=&#8201;5,414 each arm; HR 0.65, 95% CI 0.34&#8211;1.25), with consistent results in both prevalent and incident users.
</p><p>
Tsai et al.
<xref rid="JR250061ra-37" ref-type="bibr">37</xref>
investigated potential differences in VTE risk between SGLT2 inhibitors and GLP-1 receptor agonists, as well as between SGLT2 inhibitors and DPP-4 inhibitors, using the same dataset. Their findings aligned with previous studies, indicating no association between SGLT2 inhibitors and VTE risk (HR 1.39, 95% CI 0.32&#8211;5.94) compared with GLP-1 receptor agonists in T2DM patients, but a lower VTE risk was observed compared with DPP-4 inhibitors (HR 0.70, 95% CI 0.59&#8211;0.84). In the same study, the authors performed a meta-analysis that combined their data with three other observational studies,
<xref rid="JR250061ra-49" ref-type="bibr">49</xref>
<xref rid="JR250061ra-51" ref-type="bibr">51</xref>
<xref rid="JR250061ra-52" ref-type="bibr">52</xref>
and the results remained unchanged.
</p></sec></sec><sec><title>Discussion</title><p>
This review examined the associations of novel antidiabetic drugs, including GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors, with the risk of VTE. The review confirmed the scarcity of data on this topic, as only 25 relevant studies were identified. Although seven of these studies were meta-analyses of RCTs, the total number of VTE events included across these RCTs was very limited. This limitation likely arises because the sample sizes of such RCTs are often determined based on primary efficacy outcomes, making them underpowered to detect effects on rare safety outcomes like VTE, especially given the relatively short follow-up periods. Furthermore, recent RCTs involving GLP-1 receptor agonists and SGLT2 inhibitors included populations with or at high risk of cardiovascular diseases, who may already be receiving antithrombotic therapy (e.g., &#8764;60%
<xref rid="JR250061ra-117" ref-type="bibr">117</xref>
), thereby further reducing the absolute risk of VTE. Nevertheless, future RCTs are still encouraged to include VTE, including both DVT and PE, as a secondary outcome. Considering the potential effect modification by subtype of the same drug class or by patient characteristics, as suggested by some studies,
<xref rid="JR250061ra-42" ref-type="bibr">42</xref>
<xref rid="JR250061ra-48" ref-type="bibr">48</xref>
more research, both RCTs and observational studies, is undoubtedly needed.
</p><p>
This review also revealed significant inconsistency in the available evidence, with some studies indicating that GLP-1 receptor agonists or DPP-4 inhibitors may be linked to an increased risk of VTE, while SGLT2 inhibitors do not appear to be associated with VTE and may even have a protective effect. Based on the current evidence (albeit still limited), it may be reasonable to infer that SGLT2 inhibitors could be preferred in the context of VTE risk, whereas it remains unclear whether GLP-1 receptor agonists or DPP-4 inhibitors influence VTE risk. Nevertheless, a statistically significant difference in VTE risk on a relative scale may still be clinically irrelevant, while data on the difference in VTE on an absolute scale are rarely reported. Given their expanding indications
<xref rid="JR250061ra-10" ref-type="bibr">10</xref>
<xref rid="JR250061ra-11" ref-type="bibr">11</xref>
<xref rid="JR250061ra-12" ref-type="bibr">12</xref>
<xref rid="JR250061ra-13" ref-type="bibr">13</xref>
<xref rid="JR250061ra-14" ref-type="bibr">14</xref>
<xref rid="JR250061ra-15" ref-type="bibr">15</xref>
<xref rid="JR250061ra-16" ref-type="bibr">16</xref>
and the health care burden related to VTE,
<xref rid="JR250061ra-131" ref-type="bibr">131</xref>
determining the effects of all these novel antidiabetic drugs on VTE risk is of great clinical importance, especially as these medications, particularly SGLT2 inhibitors and GLP-1 receptor agonists, are increasingly being prescribed to patients for whom VTE risk is a consideration.
</p><p>
Obtaining high-quality evidence regarding the association of novel antidiabetic drugs with VTE risk is challenging. Given the low absolute incidence of VTE at the population level, conducting an RCT with sufficient statistical power to evaluate the effect of these drugs on VTE could be impractical. Observational studies utilizing routinely collected health care data might be a more feasible and even preferable approach, as their findings are more generalizable to everyday clinical practice. Nonetheless, there are challenges to this approach. First, these medications, particularly SGLT2 inhibitors and GLP-1 receptor agonists, are relatively new, and accumulating large-scale data on their use will require time. Second, compared with other antidiabetic drugs, these agents are often prescribed to patients with high cardiovascular risk, chronic kidney disease, or obesity, making it challenging to adequately address confounding by indication, although an active comparator new-user study design may help alleviate this issue.
<xref rid="JR250061ra-132" ref-type="bibr">132</xref>
Comparing SGLT2 inhibitors to GLP-1 receptor agonists could be an option, as these drugs are sometimes considered alternatives.
<xref rid="JR250061ra-11" ref-type="bibr">11</xref>
</p><p>
In addition to clinical research on VTE, fundamental, preclinical research, as well as clinical research on intermediate endpoints, should be encouraged to explore potential effects&#8212;either beneficial or harmful&#8212;on thrombosis and hemostasis, where currently available evidence is also scarce. An animal study by Chien et al.
<xref rid="JR250061ra-133" ref-type="bibr">133</xref>
demonstrated that treatment with exendin-4 (a GLP-1 receptor agonist) restored normal endothelial morphology and improved arteriovenous fistula function in rats with chronic kidney disease. Steven et al.
<xref rid="JR250061ra-134" ref-type="bibr">134</xref>
found that GLP-1 receptor activation in platelets by linagliptin (a DPP-4 inhibitor) and liraglutide (a GLP-1 receptor agonist) significantly attenuated endotoxemia-induced microvascular thrombosis. An animal study by Evlakhov et al.
<xref rid="JR250061ra-135" ref-type="bibr">135</xref>
showed that pretreatment with dapagliflozin (an SGLT2 inhibitor) reduced endothelial permeability under conditions of PE. An RCT conducted among obese, non-diabetic/prediabetic patients undergoing hip surgery (receiving dabigatran for anticoagulation postsurgery) investigated the effects of liraglutide versus placebo on coagulation activation.
<xref rid="JR250061ra-136" ref-type="bibr">136</xref>
No changes were observed in coagulation activation, but factor VIII levels were significantly higher 2&#8201;hours postsurgery, while D-dimer levels were significantly lower 3 days postsurgery. Another RCT involving overweight and/or insulin-resistant women with polycystic ovary syndrome who received liraglutide or placebo found no effect on endogenous thrombin potential, though there was a trend toward decreased plasminogen activator inhibitor-1.
<xref rid="JR250061ra-137" ref-type="bibr">137</xref>
These studies might provide valuable insights into the potential mechanisms and effects of these novel medications on VTE.
</p><p>
It is important to note that all the studies reviewed focused exclusively on the risk of primary VTE. Thus, a knowledge gap remains regarding whether these novel antidiabetic drugs affect the risk of VTE recurrence in a population with a history of VTE, as well as the efficacy or safety of anticoagulants used for preventing VTE recurrence. Given the moderately high absolute risk of VTE recurrence,
<xref rid="JR250061ra-138" ref-type="bibr">138</xref>
from a statistical power perspective, it may be more feasible to conduct studies on VTE recurrence. There is also limited knowledge about potential interactions between anticoagulants and novel antithrombotic agents, with most of the available evidence pertaining to warfarin in healthy individuals.
<xref rid="JR250061ra-139" ref-type="bibr">139</xref>
<xref rid="JR250061ra-140" ref-type="bibr">140</xref>
<xref rid="JR250061ra-141" ref-type="bibr">141</xref>
<xref rid="OR250061ra-142" ref-type="bibr">142</xref>
These areas represent important future research directions.
</p></sec><sec><title>Conclusion</title><p>In conclusion, the current evidence regarding the potential effects of novel antidiabetic drugs on VTE risk is very limited and inconsistent. Further studies are warranted to bridge this knowledge gap and guide clinical decision-making.</p></sec></body><back><fn-group><fn fn-type="COI-statement" id="d35e138"><p><bold>Conflict of Interest</bold> None declared.</p></fn></fn-group><fn-group><title>Declaration of GenAI Use</title><fn id="FN250061ra-3"><p>GPT-4o with canvas by OpenAI was subsequently used to enhance language and clarity, with all suggested changes reviewed through Microsoft Word's Track Changes feature. Each modification was manually assessed for appropriateness, with additional revisions made by the authors as necessary. Plagiarism checks were conducted on both the initial and edited drafts using iThenticate. Upon reasonable request, the draft and track changes documentation can be provided by the corresponding author.</p></fn></fn-group><fn-group><title>Authors' Contributions</title><fn id="FN250061ra-4"><p>Q.C. conducted the literature search and independently wrote the initial draft of the manuscript before it underwent language editing. All other authors contributed to the critical revision of the manuscript for important intellectual content.</p></fn></fn-group><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM250061ra-1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10-1055-a-2546-0353-s250061ra.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material</p></caption><caption><p>Supplementary Material</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="JR250061ra-1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blind</surname><given-names>E</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>H</given-names></name><name name-style="western"><surname>Dunder</surname><given-names>K</given-names></name><name name-style="western"><surname>de Graeff</surname><given-names>P A</given-names></name></person-group><article-title>The European Medicines Agency's approval of new medicines for type 2 diabetes</article-title><source>Diabetes Obes Metab</source><year>2018</year><volume>20</volume><issue>09</issue><fpage>2059</fpage><lpage>2063</lpage><pub-id pub-id-type="pmid">29740935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.13349</pub-id><pub-id pub-id-type="pmcid">PMC6667915</pub-id></mixed-citation></ref><ref id="JR250061ra-2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahl&#233;n</surname><given-names>A D</given-names></name><name name-style="western"><surname>Dashi</surname><given-names>G</given-names></name><name name-style="western"><surname>Maslov</surname><given-names>I</given-names></name></person-group><etal/><article-title>Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales</article-title><source>Front Pharmacol</source><year>2022</year><volume>12</volume><fpage>807548</fpage><pub-id pub-id-type="pmid">35126141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.807548</pub-id><pub-id pub-id-type="pmcid">PMC8807560</pub-id></mixed-citation></ref><ref id="JR250061ra-3"><label>3</label><mixed-citation publication-type="journal"><collab>EMPA-REG OUTCOME Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Zinman</surname><given-names>B</given-names></name><name name-style="western"><surname>Wanner</surname><given-names>C</given-names></name><name name-style="western"><surname>Lachin</surname><given-names>J M</given-names></name></person-group><etal/><article-title>Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><issue>22</issue><fpage>2117</fpage><lpage>2128</lpage><pub-id pub-id-type="pmid">26378978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1504720</pub-id></mixed-citation></ref><ref id="JR250061ra-4"><label>4</label><mixed-citation publication-type="journal"><collab>EMPA-REG OUTCOME Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Wanner</surname><given-names>C</given-names></name><name name-style="western"><surname>Inzucchi</surname><given-names>S E</given-names></name><name name-style="western"><surname>Lachin</surname><given-names>J M</given-names></name></person-group><etal/><article-title>Empagliflozin and progression of kidney disease in type 2 diabetes</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>04</issue><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">27299675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1515920</pub-id></mixed-citation></ref><ref id="JR250061ra-5"><label>5</label><mixed-citation publication-type="journal"><collab>LEADER Steering Committee </collab><collab>LEADER Trial Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Marso</surname><given-names>S P</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>G H</given-names></name><name name-style="western"><surname>Brown-Frandsen</surname><given-names>K</given-names></name></person-group><etal/><article-title>Liraglutide and cardiovascular outcomes in type 2 diabetes</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>04</issue><fpage>311</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">27295427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1603827</pub-id><pub-id pub-id-type="pmcid">PMC4985288</pub-id></mixed-citation></ref><ref id="JR250061ra-6"><label>6</label><mixed-citation publication-type="journal"><collab>LEADER Steering Committee and Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Mann</surname><given-names>J FE</given-names></name><name name-style="western"><surname>&#216;rsted</surname><given-names>D D</given-names></name><name name-style="western"><surname>Brown-Frandsen</surname><given-names>K</given-names></name></person-group><etal/><article-title>Liraglutide and renal outcomes in type 2 diabetes</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><issue>09</issue><fpage>839</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">28854085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1616011</pub-id></mixed-citation></ref><ref id="JR250061ra-7"><label>7</label><mixed-citation publication-type="journal"><collab>DAPA-HF Trial Committees and Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>McMurray</surname><given-names>J JV</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>S D</given-names></name><name name-style="western"><surname>Inzucchi</surname><given-names>S E</given-names></name></person-group><etal/><article-title>Dapagliflozin in patients with heart failure and reduced ejection fraction</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><issue>21</issue><fpage>1995</fpage><lpage>2008</lpage><pub-id pub-id-type="pmid">31535829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1911303</pub-id></mixed-citation></ref><ref id="JR250061ra-8"><label>8</label><mixed-citation publication-type="journal"><collab>DAPA-CKD Trial Committees and Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Heerspink</surname><given-names>H JL</given-names></name><name name-style="western"><surname>Stef&#225;nsson</surname><given-names>B V</given-names></name><name name-style="western"><surname>Correa-Rotter</surname><given-names>R</given-names></name></person-group><etal/><article-title>Dapagliflozin in patients with chronic kidney disease</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>15</issue><fpage>1436</fpage><lpage>1446</lpage><pub-id pub-id-type="pmid">32970396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2024816</pub-id></mixed-citation></ref><ref id="JR250061ra-9"><label>9</label><mixed-citation publication-type="journal"><collab>SELECT Trial Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Lincoff</surname><given-names>A M</given-names></name><name name-style="western"><surname>Brown-Frandsen</surname><given-names>K</given-names></name><name name-style="western"><surname>Colhoun</surname><given-names>H M</given-names></name></person-group><etal/><article-title>Semaglutide and cardiovascular outcomes in obesity without diabetes</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><issue>24</issue><fpage>2221</fpage><lpage>2232</lpage><pub-id pub-id-type="pmid">37952131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2307563</pub-id></mixed-citation></ref><ref id="JR250061ra-10"><label>10</label><mixed-citation publication-type="journal"><collab>American Diabetes Association Professional Practice Committee </collab><article-title>9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024</article-title><source>Diabetes Care</source><year>2024</year><volume>47</volume><supplement>01</supplement><fpage>S158</fpage><lpage>S178</lpage><pub-id pub-id-type="pmid">38078590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc24-S009</pub-id><pub-id pub-id-type="pmcid">PMC10725810</pub-id></mixed-citation></ref><ref id="JR250061ra-11"><label>11</label><mixed-citation publication-type="journal"><collab>American Diabetes Association Professional Practice Committee </collab><article-title>10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024</article-title><source>Diabetes Care</source><year>2024</year><volume>47</volume><supplement>01</supplement><fpage>S179</fpage><lpage>S218</lpage><pub-id pub-id-type="pmid">38078592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc24-S010</pub-id><pub-id pub-id-type="pmcid">PMC10725811</pub-id></mixed-citation></ref><ref id="JR250061ra-12"><label>12</label><mixed-citation publication-type="journal"><collab>ESC Scientific Document Group </collab><person-group person-group-type="author"><name name-style="western"><surname>McDonagh</surname><given-names>T A</given-names></name><name name-style="western"><surname>Metra</surname><given-names>M</given-names></name><name name-style="western"><surname>Adamo</surname><given-names>M</given-names></name></person-group><etal/><article-title>2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure</article-title><source>Eur Heart J</source><year>2023</year><volume>44</volume><issue>37</issue><fpage>3627</fpage><lpage>3639</lpage><pub-id pub-id-type="pmid">37622666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehad195</pub-id></mixed-citation></ref><ref id="JR250061ra-13"><label>13</label><mixed-citation publication-type="journal"><collab>ESC Scientific Document Group </collab><person-group person-group-type="author"><name name-style="western"><surname>Vrints</surname><given-names>C</given-names></name><name name-style="western"><surname>Andreotti</surname><given-names>F</given-names></name><name name-style="western"><surname>Koskinas</surname><given-names>K C</given-names></name></person-group><etal/><article-title>2024 ESC Guidelines for the management of chronic coronary syndromes</article-title><source>Eur Heart J</source><year>2024</year><volume>45</volume><issue>36</issue><fpage>3415</fpage><lpage>3537</lpage><pub-id pub-id-type="pmid">39210710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehae177</pub-id></mixed-citation></ref><ref id="JR250061ra-14"><label>14</label><mixed-citation publication-type="journal"><collab>ESC Scientific Document Group </collab><person-group person-group-type="author"><name name-style="western"><surname>Marx</surname><given-names>N</given-names></name><name name-style="western"><surname>Federici</surname><given-names>M</given-names></name><name name-style="western"><surname>Sch&#252;tt</surname><given-names>K</given-names></name></person-group><etal/><article-title>2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes</article-title><source>Eur Heart J</source><year>2023</year><volume>44</volume><issue>39</issue><fpage>4043</fpage><lpage>4140</lpage><pub-id pub-id-type="pmid">37622663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehad192</pub-id></mixed-citation></ref><ref id="JR250061ra-15"><label>15</label><mixed-citation publication-type="journal"><collab>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group </collab><article-title>KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</article-title><source>Kidney Int</source><year>2024</year><volume>105</volume>(4S):<fpage>S117</fpage><lpage>S314</lpage><pub-id pub-id-type="pmid">38490803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2023.10.018</pub-id></mixed-citation></ref><ref id="JR250061ra-16"><label>16</label><mixed-citation publication-type="journal"><collab>AGA Clinical Guidelines Committee </collab><person-group person-group-type="author"><name name-style="western"><surname>Grunvald</surname><given-names>E</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R</given-names></name><name name-style="western"><surname>Hernaez</surname><given-names>R</given-names></name></person-group><etal/><article-title>AGA Clinical Practice Guideline on pharmacological interventions for adults with obesity</article-title><source>Gastroenterology</source><year>2022</year><volume>163</volume><issue>05</issue><fpage>1198</fpage><lpage>1225</lpage><pub-id pub-id-type="pmid">36273831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2022.08.045</pub-id></mixed-citation></ref><ref id="JR250061ra-17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>S T</given-names></name><name name-style="western"><surname>Patorno</surname><given-names>E</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>M</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S C</given-names></name><name name-style="western"><surname>Paik</surname><given-names>J M</given-names></name></person-group><article-title>Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study</article-title><source>Diabetes Care</source><year>2021</year><volume>44</volume><issue>10</issue><fpage>2293</fpage><lpage>2301</lpage><pub-id pub-id-type="pmid">34344714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc21-0529</pub-id><pub-id pub-id-type="pmcid">PMC8929186</pub-id></mixed-citation></ref><ref id="JR250061ra-18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Csatordai</surname><given-names>M</given-names></name><name name-style="western"><surname>Benk&#337;</surname><given-names>R</given-names></name><name name-style="western"><surname>Matuz</surname><given-names>M</given-names></name></person-group><etal/><article-title>Trends and regional differences in antidiabetic medication use: a nationwide retrospective observational study</article-title><source>Diabetol Metab Syndr</source><year>2024</year><volume>16</volume><issue>01</issue><fpage>88</fpage><pub-id pub-id-type="pmid">38658983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13098-024-01334-8</pub-id><pub-id pub-id-type="pmcid">PMC11044416</pub-id></mixed-citation></ref><ref id="JR250061ra-19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramzan</surname><given-names>S</given-names></name><name name-style="western"><surname>Timmins</surname><given-names>P</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>S S</given-names></name><name name-style="western"><surname>Babar</surname><given-names>Z U</given-names></name></person-group><article-title>Trends in global prescribing of antidiabetic medicines in primary care: A systematic review of literature between 2000-2018</article-title><source>Prim Care Diabetes</source><year>2019</year><volume>13</volume><issue>05</issue><fpage>409</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">31213359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pcd.2019.05.009</pub-id></mixed-citation></ref><ref id="JR250061ra-20"><label>20</label><mixed-citation publication-type="journal"><collab>ESC Scientific Document Group </collab><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>R A</given-names></name><name name-style="western"><surname>Rossello</surname><given-names>X</given-names></name><name name-style="western"><surname>Coughlan</surname><given-names>J J</given-names></name></person-group><etal/><article-title>2023 ESC Guidelines for the management of acute coronary syndromes</article-title><source>Eur Heart J</source><year>2023</year><volume>44</volume><issue>38</issue><fpage>3720</fpage><lpage>3826</lpage><pub-id pub-id-type="pmid">37622654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehad191</pub-id></mixed-citation></ref><ref id="JR250061ra-21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kristensen</surname><given-names>S L</given-names></name><name name-style="western"><surname>R&#248;rth</surname><given-names>R</given-names></name><name name-style="western"><surname>Jhund</surname><given-names>P S</given-names></name></person-group><etal/><article-title>Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials</article-title><source>Lancet Diabetes Endocrinol</source><year>2019</year><volume>7</volume><issue>10</issue><fpage>776</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">31422062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(19)30249-9</pub-id></mixed-citation></ref><ref id="JR250061ra-22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>E J</given-names></name><name name-style="western"><surname>Folsom</surname><given-names>A R</given-names></name><name name-style="western"><surname>Lutsey</surname><given-names>P L</given-names></name></person-group><etal/><article-title>Diabetes mellitus and venous thromboembolism: A systematic review and meta-analysis</article-title><source>Diabetes Res Clin Pract</source><year>2016</year><volume>111</volume><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">26612139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2015.10.019</pub-id><pub-id pub-id-type="pmcid">PMC4752919</pub-id></mixed-citation></ref><ref id="JR250061ra-23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldhaber</surname><given-names>S Z</given-names></name></person-group><article-title>Venous thromboembolism in heart failure patients: pathophysiology, predictability, prevention</article-title><source>J Am Coll Cardiol</source><year>2020</year><volume>75</volume><issue>02</issue><fpage>159</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">31948644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2019.11.028</pub-id></mixed-citation></ref><ref id="JR250061ra-24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L V</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name></person-group><article-title>Venous thromboembolism in kidney diseases and genetic predisposition</article-title><source>Kidney Dis (Basel)</source><year>2022</year><volume>8</volume><issue>03</issue><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">35702706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000523777</pub-id><pub-id pub-id-type="pmcid">PMC9149476</pub-id></mixed-citation></ref><ref id="JR250061ra-25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>De Staercke</surname><given-names>C</given-names></name><name name-style="western"><surname>Hooper</surname><given-names>W C</given-names></name></person-group><article-title>The effects of obesity on venous thromboembolism: A review</article-title><source>Open J Prev Med</source><year>2012</year><volume>2</volume><issue>04</issue><fpage>499</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">26236563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4236/ojpm.2012.24069</pub-id><pub-id pub-id-type="pmcid">PMC4520798</pub-id></mixed-citation></ref><ref id="JR250061ra-26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Douketis</surname><given-names>J D</given-names></name><name name-style="western"><surname>Foster</surname><given-names>G A</given-names></name><name name-style="western"><surname>Crowther</surname><given-names>M A</given-names></name><name name-style="western"><surname>Prins</surname><given-names>M H</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>J S</given-names></name></person-group><article-title>Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy</article-title><source>Arch Intern Med</source><year>2000</year><volume>160</volume><issue>22</issue><fpage>3431</fpage><lpage>3436</lpage><pub-id pub-id-type="pmid">11112236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archinte.160.22.3431</pub-id></mixed-citation></ref><ref id="JR250061ra-27"><label>27</label><mixed-citation publication-type="journal"><collab>GARFIELD-VTE Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Goto</surname><given-names>S</given-names></name><name name-style="western"><surname>Haas</surname><given-names>S</given-names></name><name name-style="western"><surname>Ageno</surname><given-names>W</given-names></name></person-group><etal/><article-title>Assessment of outcomes among patients with venous thromboembolism with and without chronic kidney disease</article-title><source>JAMA Netw Open</source><year>2020</year><volume>3</volume><issue>10</issue><fpage>e2022886</fpage><pub-id pub-id-type="pmid">33112399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.22886</pub-id><pub-id pub-id-type="pmcid">PMC7593818</pub-id></mixed-citation></ref><ref id="JR250061ra-28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eichinger</surname><given-names>S</given-names></name><name name-style="western"><surname>Hron</surname><given-names>G</given-names></name><name name-style="western"><surname>Bialonczyk</surname><given-names>C</given-names></name></person-group><etal/><article-title>Overweight, obesity, and the risk of recurrent venous thromboembolism</article-title><source>Arch Intern Med</source><year>2008</year><volume>168</volume><issue>15</issue><fpage>1678</fpage><lpage>1683</lpage><pub-id pub-id-type="pmid">18695082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archinte.168.15.1678</pub-id></mixed-citation></ref><ref id="JR250061ra-29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>L K</given-names></name><name name-style="western"><surname>Kline</surname><given-names>J A</given-names></name></person-group><article-title>Metabolic syndrome increases risk of venous thromboembolism recurrence after acute pulmonary embolism</article-title><source>Ann Am Thorac Soc</source><year>2020</year><volume>17</volume><issue>07</issue><fpage>821</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">32187500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1513/AnnalsATS.201907-518OC</pub-id><pub-id pub-id-type="pmcid">PMC7328175</pub-id></mixed-citation></ref><ref id="JR250061ra-30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fusaroli</surname><given-names>M</given-names></name><name name-style="western"><surname>Salvo</surname><given-names>F</given-names></name><name name-style="western"><surname>Begaud</surname><given-names>B</given-names></name></person-group><etal/><article-title>The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and statement</article-title><source>Drug Saf</source><year>2024</year><volume>47</volume><issue>06</issue><fpage>575</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">38713346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40264-024-01421-9</pub-id><pub-id pub-id-type="pmcid">PMC11116242</pub-id></mixed-citation></ref><ref id="JR250061ra-31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>D G</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H R</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>M</given-names></name><name name-style="western"><surname>Duan</surname><given-names>X Y</given-names></name></person-group><article-title>Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials</article-title><source>Endocr J</source><year>2021</year><volume>68</volume><issue>06</issue><fpage>739</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">34024887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1507/endocrj.EJ21-0129</pub-id></mixed-citation></ref><ref id="JR250061ra-32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>X X</given-names></name><name name-style="western"><surname>Li</surname><given-names>W Q</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Z K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H B</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name></person-group><article-title>Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta-analysis</article-title><source>J Clin Pharm Ther</source><year>2022</year><volume>47</volume><issue>05</issue><fpage>636</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">34939679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcpt.13588</pub-id></mixed-citation></ref><ref id="JR250061ra-33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Oliveira Almeida</surname><given-names>G</given-names></name><name name-style="western"><surname>Nienk&#246;tter</surname><given-names>T F</given-names></name><name name-style="western"><surname>Balieiro</surname><given-names>C CA</given-names></name></person-group><etal/><article-title>Cardiovascular benefits of GLP-1 receptor agonists in patients living with obesity or overweight: a meta-analysis of randomized controlled trials</article-title><source>Am J Cardiovasc Drugs</source><year>2024</year><volume>24</volume><issue>04</issue><fpage>509</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">38734847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40256-024-00647-3</pub-id></mixed-citation></ref><ref id="JR250061ra-34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D H</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Y X</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wen</surname><given-names>F</given-names></name></person-group><article-title>A comprehensive meta-analysis on the association of SGLT2is and GLP-1RAs with vascular diseases, digestive diseases and fractures</article-title><source>Acta Diabetol</source><year>2024</year><volume>61</volume><issue>09</issue><fpage>1097</fpage><lpage>1105</lpage><pub-id pub-id-type="pmid">38714558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00592-024-02289-y</pub-id></mixed-citation></ref><ref id="JR250061ra-35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xin</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name></person-group><article-title>Dipeptidyl peptidase 4 inhibitors and venous thromboembolism risk in patients with type 2 diabetes: a meta-analysis of cardiovascular outcomes trials</article-title><source>Thromb Haemost</source><year>2021</year><volume>121</volume><issue>01</issue><fpage>106</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">32772351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0040-1715444</pub-id></mixed-citation></ref><ref id="JR250061ra-36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>A</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name></person-group><article-title>Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis</article-title><source>Diabetes Metab Res Rev</source><year>2020</year><volume>36</volume><issue>01</issue><fpage>e3174</fpage><pub-id pub-id-type="pmid">31050384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dmrr.3174</pub-id></mixed-citation></ref><ref id="JR250061ra-37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>H R</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y J</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>J I</given-names></name></person-group><etal/><article-title>Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis</article-title><source>Diabetes Metab Res Rev</source><year>2024</year><volume>40</volume><issue>02</issue><fpage>e3739</fpage><pub-id pub-id-type="pmid">37862117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dmrr.3739</pub-id></mixed-citation></ref><ref id="JR250061ra-38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>A</given-names></name><name name-style="western"><surname>Frederich</surname><given-names>R</given-names></name></person-group><etal/><article-title>Safety of ertugliflozin in patients with type 2 diabetes mellitus: pooled analysis of seven Phase 3 randomized controlled trials</article-title><source>Diabetes Ther</source><year>2020</year><volume>11</volume><issue>06</issue><fpage>1347</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">32372382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13300-020-00803-3</pub-id><pub-id pub-id-type="pmcid">PMC7261307</pub-id></mixed-citation></ref><ref id="JR250061ra-39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St&#246;llberger</surname><given-names>C</given-names></name><name name-style="western"><surname>Finsterer</surname><given-names>J</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>B</given-names></name></person-group><article-title>Adverse events and drug-drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure</article-title><source>Expert Rev Cardiovasc Ther</source><year>2023</year><volume>21</volume><issue>11</issue><fpage>803</fpage><lpage>816</lpage><pub-id pub-id-type="pmid">37856368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14779072.2023.2273900</pub-id></mixed-citation></ref><ref id="JR250061ra-40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caparrotta</surname><given-names>T M</given-names></name><name name-style="western"><surname>Greenhalgh</surname><given-names>A M</given-names></name><name name-style="western"><surname>Osinski</surname><given-names>K</given-names></name></person-group><etal/><article-title>Sodium-glucose co-transporter 2 inhibitors (SGLT2i) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies</article-title><source>Diabetes Ther</source><year>2021</year><volume>12</volume><issue>04</issue><fpage>991</fpage><lpage>1028</lpage><pub-id pub-id-type="pmid">33665777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13300-021-01004-2</pub-id><pub-id pub-id-type="pmcid">PMC7994468</pub-id></mixed-citation></ref><ref id="JR250061ra-41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnaud</surname><given-names>M</given-names></name><name name-style="western"><surname>B&#233;gaud</surname><given-names>B</given-names></name><name name-style="western"><surname>Thiessard</surname><given-names>F</given-names></name></person-group><etal/><article-title>An automated system combining safety signal detection and prioritization from healthcare databases: a pilot study</article-title><source>Drug Saf</source><year>2018</year><volume>41</volume><issue>04</issue><fpage>377</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">29185236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40264-017-0618-y</pub-id></mixed-citation></ref><ref id="JR250061ra-42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gouverneur</surname><given-names>A</given-names></name><name name-style="western"><surname>Lair</surname><given-names>A</given-names></name><name name-style="western"><surname>Arnaud</surname><given-names>M</given-names></name></person-group><etal/><article-title>DPP-4 inhibitors and venous thromboembolism: an analysis of the WHO spontaneous reporting database</article-title><source>Lancet Diabetes Endocrinol</source><year>2020</year><volume>8</volume><issue>05</issue><fpage>365</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">32333868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(20)30112-1</pub-id></mixed-citation></ref><ref id="JR250061ra-43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>W</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name></person-group><etal/><article-title>Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system</article-title><source>Int J Clin Pharm</source><year>2020</year><volume>42</volume><issue>05</issue><fpage>1364</fpage><lpage>1368</lpage><pub-id pub-id-type="pmid">32951183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11096-020-01037-w</pub-id></mixed-citation></ref><ref id="OR250061ra-44"><label>44</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Elsabbagh</surname><given-names>Z</given-names></name><name name-style="western"><surname>Haft</surname><given-names>M</given-names></name><name name-style="western"><surname>Murali</surname><given-names>S</given-names></name></person-group><etal/><article-title>Does use of GLP-1 agonists increase postoperative complications in patients undergoing shoulder arthroplasty?</article-title>J Shoulder Elbow Surg 2024;S1058-2746(24)00646-3<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jse.2024.07.045</pub-id><pub-id pub-id-type="pmid">39322005</pub-id></mixed-citation></ref><ref id="JR250061ra-45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seddio</surname><given-names>A E</given-names></name><name name-style="western"><surname>Moran</surname><given-names>J</given-names></name><name name-style="western"><surname>Gouzoulis</surname><given-names>M J</given-names></name></person-group><etal/><article-title>Lower risk of postoperative complications and rotator cuff retear associated with semaglutide use in patients with type ii diabetes mellitus undergoing arthroscopic rotator cuff repair</article-title><source>Arthroscopy</source><year>2025</year><volume>41</volume><issue>02</issue><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">39490542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arthro.2024.09.057</pub-id></mixed-citation></ref><ref id="JR250061ra-46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawand</surname><given-names>J J</given-names></name><name name-style="western"><surname>Tansey</surname><given-names>P J</given-names></name><name name-style="western"><surname>Ghali</surname><given-names>A</given-names></name></person-group><etal/><article-title>Glucagon-like peptide-1 receptor agonist use is associated with increased risk of perioperative complication and readmission following shoulder arthroplasty</article-title><source>J Shoulder Elbow Surg</source><year>2024</year><fpage>S1058</fpage><lpage>2746</lpage>(24)00798-5<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jse.2024.09.012</pub-id><pub-id pub-id-type="pmid">39528042</pub-id></mixed-citation></ref><ref id="JR250061ra-47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>B I</given-names></name><name name-style="western"><surname>LaValva</surname><given-names>S M</given-names></name><name name-style="western"><surname>Parks</surname><given-names>M L</given-names></name><name name-style="western"><surname>Sculco</surname><given-names>P K</given-names></name><name name-style="western"><surname>Della Valle</surname><given-names>A G</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G C</given-names></name></person-group><article-title>Glucagon-Like Peptide-1 Receptor Agonists Decrease Medical and Surgical Complications in Morbidly Obese Patients Undergoing Primary TKA</article-title><source>J Bone Joint Surg Am</source><year>2025</year><volume>107</volume><issue>04</issue><fpage>348</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">39719003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2106/JBJS.24.00468</pub-id></mixed-citation></ref><ref id="JR250061ra-48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deischinger</surname><given-names>C</given-names></name><name name-style="western"><surname>Dervic</surname><given-names>E</given-names></name><name name-style="western"><surname>Nopp</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaleta</surname><given-names>M</given-names></name><name name-style="western"><surname>Klimek</surname><given-names>P</given-names></name><name name-style="western"><surname>Kautzky-Willer</surname><given-names>A</given-names></name></person-group><article-title>Diabetes mellitus is associated with a higher relative risk for venous thromboembolism in females than in males</article-title><source>Diabetes Res Clin Pract</source><year>2022</year><volume>194</volume><fpage>110190</fpage><pub-id pub-id-type="pmid">36471550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2022.110190</pub-id></mixed-citation></ref><ref id="JR250061ra-49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>P</given-names></name><name name-style="western"><surname>Svanstr&#246;m</surname><given-names>H</given-names></name><name name-style="western"><surname>Melbye</surname><given-names>M</given-names></name></person-group><etal/><article-title>Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study</article-title><source>BMJ</source><year>2018</year><volume>363</volume><fpage>k4365</fpage><pub-id pub-id-type="pmid">30429124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.k4365</pub-id><pub-id pub-id-type="pmcid">PMC6233755</pub-id></mixed-citation></ref><ref id="JR250061ra-50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patil</surname><given-names>T</given-names></name><name name-style="western"><surname>Cook</surname><given-names>M</given-names></name><name name-style="western"><surname>Hobson</surname><given-names>J</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>A</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A</given-names></name></person-group><article-title>Evaluating the safety of sodium-glucose cotransporter-2 inhibitors in a Nationwide Veterans Health Administration Observational Cohort Study</article-title><source>Am J Cardiol</source><year>2023</year><volume>201</volume><fpage>281</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">37393731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjcard.2023.06.016</pub-id></mixed-citation></ref><ref id="JR250061ra-51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmedt</surname><given-names>N</given-names></name><name name-style="western"><surname>Enders</surname><given-names>D</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J</given-names></name><name name-style="western"><surname>Garbe</surname><given-names>E</given-names></name><name name-style="western"><surname>Douros</surname><given-names>A</given-names></name></person-group><article-title>Sodium-glucose co-transporter 2 inhibitors and the risk of venous thromboembolism in patients with type 2 diabetes: A cohort study</article-title><source>Am J Med</source><year>2021</year><volume>134</volume><issue>05</issue><fpage>606</fpage><lpage>6.13E8</lpage><pub-id pub-id-type="pmid">33316246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2020.10.046</pub-id></mixed-citation></ref><ref id="JR250061ra-52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aloe</surname><given-names>S</given-names></name><name name-style="western"><surname>Filliter</surname><given-names>C</given-names></name><name name-style="western"><surname>Salmasi</surname><given-names>S</given-names></name></person-group><etal/><article-title>Sodium-glucose cotransporter 2 inhibitors and the risk of venous thromboembolism: A population-based cohort study</article-title><source>Br J Clin Pharmacol</source><year>2023</year><volume>89</volume><issue>09</issue><fpage>2902</fpage><lpage>2914</lpage><pub-id pub-id-type="pmid">37183930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.15787</pub-id></mixed-citation></ref><ref id="JR250061ra-53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>H R</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y J</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>J I</given-names></name></person-group><etal/><article-title>Use of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes and the incidence of retinal vein occlusion in Taiwan</article-title><source>Invest Ophthalmol Vis Sci</source><year>2024</year><volume>65</volume><issue>06</issue><fpage>19</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.65.6.19</pub-id><pub-id pub-id-type="pmcid">PMC11174139</pub-id><pub-id pub-id-type="pmid">38864813</pub-id></mixed-citation></ref><ref id="JR250061ra-54"><label>54</label><mixed-citation publication-type="journal"><collab>PIONEER 3 Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Rosenstock</surname><given-names>J</given-names></name><name name-style="western"><surname>Allison</surname><given-names>D</given-names></name><name name-style="western"><surname>Birkenfeld</surname><given-names>A L</given-names></name></person-group><etal/><article-title>Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial</article-title><source>JAMA</source><year>2019</year><volume>321</volume><issue>15</issue><fpage>1466</fpage><lpage>1480</lpage><pub-id pub-id-type="pmid">30903796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.2942</pub-id><pub-id pub-id-type="pmcid">PMC6484814</pub-id></mixed-citation></ref><ref id="JR250061ra-55"><label>55</label><mixed-citation publication-type="journal"><collab>PIONEER 6 Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Husain</surname><given-names>M</given-names></name><name name-style="western"><surname>Birkenfeld</surname><given-names>A L</given-names></name><name name-style="western"><surname>Donsmark</surname><given-names>M</given-names></name></person-group><etal/><article-title>Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><issue>09</issue><fpage>841</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">31185157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1901118</pub-id></mixed-citation></ref><ref id="JR250061ra-56"><label>56</label><mixed-citation publication-type="journal"><collab>PIONEER 4 investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Pratley</surname><given-names>R</given-names></name><name name-style="western"><surname>Amod</surname><given-names>A</given-names></name><name name-style="western"><surname>Hoff</surname><given-names>S T</given-names></name></person-group><etal/><article-title>Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial</article-title><source>Lancet</source><year>2019</year><volume>394</volume>(10192):<fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">31186120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)31271-1</pub-id></mixed-citation></ref><ref id="JR250061ra-57"><label>57</label><mixed-citation publication-type="journal"><collab>PIONEER 1 Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Aroda</surname><given-names>V R</given-names></name><name name-style="western"><surname>Rosenstock</surname><given-names>J</given-names></name><name name-style="western"><surname>Terauchi</surname><given-names>Y</given-names></name></person-group><etal/><article-title>PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2019</year><volume>42</volume><issue>09</issue><fpage>1724</fpage><lpage>1732</lpage><pub-id pub-id-type="pmid">31186300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc19-0749</pub-id></mixed-citation></ref><ref id="JR250061ra-58"><label>58</label><mixed-citation publication-type="journal"><collab>PIONEER 5 Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Mosenzon</surname><given-names>O</given-names></name><name name-style="western"><surname>Blicher</surname><given-names>T M</given-names></name><name name-style="western"><surname>Rosenlund</surname><given-names>S</given-names></name></person-group><etal/><article-title>Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2019</year><volume>7</volume><issue>07</issue><fpage>515</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">31189517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(19)30192-5</pub-id></mixed-citation></ref><ref id="JR250061ra-59"><label>59</label><mixed-citation publication-type="journal"><collab>PIONEER 7 investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Pieber</surname><given-names>T R</given-names></name><name name-style="western"><surname>Bode</surname><given-names>B</given-names></name><name name-style="western"><surname>Mertens</surname><given-names>A</given-names></name></person-group><etal/><article-title>Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2019</year><volume>7</volume><issue>07</issue><fpage>528</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">31189520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(19)30194-9</pub-id></mixed-citation></ref><ref id="JR250061ra-60"><label>60</label><mixed-citation publication-type="journal"><collab>PIONEER 2 Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Rodbard</surname><given-names>H W</given-names></name><name name-style="western"><surname>Rosenstock</surname><given-names>J</given-names></name><name name-style="western"><surname>Canani</surname><given-names>L H</given-names></name></person-group><etal/><article-title>Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 Trial</article-title><source>Diabetes Care</source><year>2019</year><volume>42</volume><issue>12</issue><fpage>2272</fpage><lpage>2281</lpage><pub-id pub-id-type="pmid">31530666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc19-0883</pub-id></mixed-citation></ref><ref id="JR250061ra-61"><label>61</label><mixed-citation publication-type="journal"><collab>PIONEER 8 Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Zinman</surname><given-names>B</given-names></name><name name-style="western"><surname>Aroda</surname><given-names>V R</given-names></name><name name-style="western"><surname>Buse</surname><given-names>J B</given-names></name></person-group><etal/><article-title>Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PIONEER 8 Trial</article-title><source>Diabetes Care</source><year>2019</year><volume>42</volume><issue>12</issue><fpage>2262</fpage><lpage>2271</lpage><pub-id pub-id-type="pmid">31530667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc19-0898</pub-id><pub-id pub-id-type="pmcid">PMC7364672</pub-id></mixed-citation></ref><ref id="JR250061ra-62"><label>62</label><mixed-citation publication-type="journal"><collab>PIONEER 9 investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Katagiri</surname><given-names>H</given-names></name><name name-style="western"><surname>Hamamoto</surname><given-names>Y</given-names></name></person-group><etal/><article-title>Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2020</year><volume>8</volume><issue>05</issue><fpage>377</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">32333875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(20)30075-9</pub-id></mixed-citation></ref><ref id="JR250061ra-63"><label>63</label><mixed-citation publication-type="journal"><collab>PIONEER 10 Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Yabe</surname><given-names>D</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>J</given-names></name><name name-style="western"><surname>Kaneto</surname><given-names>H</given-names></name></person-group><etal/><article-title>Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2020</year><volume>8</volume><issue>05</issue><fpage>392</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">32333876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(20)30074-7</pub-id></mixed-citation></ref><ref id="JR250061ra-64"><label>64</label><mixed-citation publication-type="journal"><collab>SUSTAIN-6 Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Marso</surname><given-names>S P</given-names></name><name name-style="western"><surname>Bain</surname><given-names>S C</given-names></name><name name-style="western"><surname>Consoli</surname><given-names>A</given-names></name></person-group><etal/><article-title>Semaglutide and cardiovascular outcomes in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>19</issue><fpage>1834</fpage><lpage>1844</lpage><pub-id pub-id-type="pmid">27633186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1607141</pub-id></mixed-citation></ref><ref id="JR250061ra-65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorli</surname><given-names>C</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>S I</given-names></name><name name-style="western"><surname>Tsoukas</surname><given-names>G M</given-names></name></person-group><etal/><article-title>Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2017</year><volume>5</volume><issue>04</issue><fpage>251</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">28110911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(17)30013-X</pub-id></mixed-citation></ref><ref id="JR250061ra-66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aroda</surname><given-names>V R</given-names></name><name name-style="western"><surname>Bain</surname><given-names>S C</given-names></name><name name-style="western"><surname>Cariou</surname><given-names>B</given-names></name></person-group><etal/><article-title>Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2017</year><volume>5</volume><issue>05</issue><fpage>355</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">28344112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(17)30085-2</pub-id></mixed-citation></ref><ref id="JR250061ra-67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahr&#233;n</surname><given-names>B</given-names></name><name name-style="western"><surname>Masmiquel</surname><given-names>L</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>H</given-names></name></person-group><etal/><article-title>Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2017</year><volume>5</volume><issue>05</issue><fpage>341</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">28385659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(17)30092-X</pub-id></mixed-citation></ref><ref id="JR250061ra-68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmann</surname><given-names>A J</given-names></name><name name-style="western"><surname>Capehorn</surname><given-names>M</given-names></name><name name-style="western"><surname>Charpentier</surname><given-names>G</given-names></name></person-group><etal/><article-title>Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial</article-title><source>Diabetes Care</source><year>2018</year><volume>41</volume><issue>02</issue><fpage>258</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">29246950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc17-0417</pub-id></mixed-citation></ref><ref id="JR250061ra-69"><label>69</label><mixed-citation publication-type="journal"><collab>SUSTAIN 7 investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Pratley</surname><given-names>R E</given-names></name><name name-style="western"><surname>Aroda</surname><given-names>V R</given-names></name><name name-style="western"><surname>Lingvay</surname><given-names>I</given-names></name></person-group><etal/><article-title>Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2018</year><volume>6</volume><issue>04</issue><fpage>275</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">29397376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(18)30024-X</pub-id></mixed-citation></ref><ref id="JR250061ra-70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodbard</surname><given-names>H W</given-names></name><name name-style="western"><surname>Lingvay</surname><given-names>I</given-names></name><name name-style="western"><surname>Reed</surname><given-names>J</given-names></name></person-group><etal/><article-title>Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): A randomized, controlled trial</article-title><source>J Clin Endocrinol Metab</source><year>2018</year><volume>103</volume><issue>06</issue><fpage>2291</fpage><lpage>2301</lpage><pub-id pub-id-type="pmid">29688502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2018-00070</pub-id><pub-id pub-id-type="pmcid">PMC5991220</pub-id></mixed-citation></ref><ref id="JR250061ra-71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinman</surname><given-names>B</given-names></name><name name-style="western"><surname>Bhosekar</surname><given-names>V</given-names></name><name name-style="western"><surname>Busch</surname><given-names>R</given-names></name></person-group><etal/><article-title>Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2019</year><volume>7</volume><issue>05</issue><fpage>356</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">30833170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(19)30066-X</pub-id></mixed-citation></ref><ref id="JR250061ra-72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capehorn</surname><given-names>M S</given-names></name><name name-style="western"><surname>Catarig</surname><given-names>A M</given-names></name><name name-style="western"><surname>Furberg</surname><given-names>J K</given-names></name></person-group><etal/><article-title>Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)</article-title><source>Diabetes Metab</source><year>2020</year><volume>46</volume><issue>02</issue><fpage>100</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">31539622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabet.2019.101117</pub-id></mixed-citation></ref><ref id="JR250061ra-73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lingvay</surname><given-names>I</given-names></name><name name-style="western"><surname>Catarig</surname><given-names>A M</given-names></name><name name-style="western"><surname>Frias</surname><given-names>J P</given-names></name></person-group><etal/><article-title>Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2019</year><volume>7</volume><issue>11</issue><fpage>834</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">31540867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(19)30311-0</pub-id></mixed-citation></ref><ref id="JR250061ra-74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><etal/><article-title>Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial</article-title><source>Diabetes Obes Metab</source><year>2021</year><volume>23</volume><issue>02</issue><fpage>404</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">33074557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.14232</pub-id><pub-id pub-id-type="pmcid">PMC7839591</pub-id></mixed-citation></ref><ref id="JR250061ra-75"><label>75</label><mixed-citation publication-type="journal"><collab>ELIXA Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Pfeffer</surname><given-names>M A</given-names></name><name name-style="western"><surname>Claggett</surname><given-names>B</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>R</given-names></name></person-group><etal/><article-title>Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><issue>23</issue><fpage>2247</fpage><lpage>2257</lpage><pub-id pub-id-type="pmid">26630143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1509225</pub-id></mixed-citation></ref><ref id="JR250061ra-76"><label>76</label><mixed-citation publication-type="journal"><collab>Harmony Outcomes committees and investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>A F</given-names></name><name name-style="western"><surname>Green</surname><given-names>J B</given-names></name><name name-style="western"><surname>Janmohamed</surname><given-names>S</given-names></name></person-group><etal/><article-title>Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial</article-title><source>Lancet</source><year>2018</year><volume>392</volume>(10157):<fpage>1519</fpage><lpage>1529</lpage><pub-id pub-id-type="pmid">30291013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)32261-X</pub-id></mixed-citation></ref><ref id="JR250061ra-77"><label>77</label><mixed-citation publication-type="journal"><collab>REWIND Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Gerstein</surname><given-names>H C</given-names></name><name name-style="western"><surname>Colhoun</surname><given-names>H M</given-names></name><name name-style="western"><surname>Dagenais</surname><given-names>G R</given-names></name></person-group><etal/><article-title>Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial</article-title><source>Lancet</source><year>2019</year><volume>394</volume>(10193):<fpage>121</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">31189511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)31149-3</pub-id></mixed-citation></ref><ref id="JR250061ra-78"><label>78</label><mixed-citation publication-type="journal"><collab>SCALE Obesity Prediabetes NN8022-1839 Study Group </collab><person-group person-group-type="author"><name name-style="western"><surname>le Roux</surname><given-names>C W</given-names></name><name name-style="western"><surname>Astrup</surname><given-names>A</given-names></name><name name-style="western"><surname>Fujioka</surname><given-names>K</given-names></name></person-group><etal/><article-title>3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume>(10077):<fpage>1399</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">28237263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)30069-7</pub-id></mixed-citation></ref><ref id="JR250061ra-79"><label>79</label><mixed-citation publication-type="journal"><collab>AMPLITUDE-O Trial Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Gerstein</surname><given-names>H C</given-names></name><name name-style="western"><surname>Sattar</surname><given-names>N</given-names></name><name name-style="western"><surname>Rosenstock</surname><given-names>J</given-names></name></person-group><etal/><article-title>Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><issue>10</issue><fpage>896</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">34215025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2108269</pub-id></mixed-citation></ref><ref id="JR250061ra-80"><label>80</label><mixed-citation publication-type="journal"><collab>SURPASS-4 Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Del Prato</surname><given-names>S</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>S E</given-names></name><name name-style="western"><surname>Pavo</surname><given-names>I</given-names></name></person-group><etal/><article-title>Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial</article-title><source>Lancet</source><year>2021</year><volume>398</volume>(10313):<fpage>1811</fpage><lpage>1824</lpage><pub-id pub-id-type="pmid">34672967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)02188-7</pub-id></mixed-citation></ref><ref id="JR250061ra-81"><label>81</label><mixed-citation publication-type="journal"><collab>SCALE Obesity and Prediabetes NN8022-1839 Study Group </collab><person-group person-group-type="author"><name name-style="western"><surname>Pi-Sunyer</surname><given-names>X</given-names></name><name name-style="western"><surname>Astrup</surname><given-names>A</given-names></name><name name-style="western"><surname>Fujioka</surname><given-names>K</given-names></name></person-group><etal/><article-title>A randomized, controlled trial of 3.0&#8201;mg of liraglutide in weight management</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><issue>01</issue><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">26132939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1411892</pub-id></mixed-citation></ref><ref id="JR250061ra-82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Neil</surname><given-names>P M</given-names></name><name name-style="western"><surname>Birkenfeld</surname><given-names>A L</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>B</given-names></name></person-group><etal/><article-title>Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial</article-title><source>Lancet</source><year>2018</year><volume>392</volume>(10148):<fpage>637</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">30122305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)31773-2</pub-id></mixed-citation></ref><ref id="JR250061ra-83"><label>83</label><mixed-citation publication-type="journal"><collab>STEP 1 Study Group </collab><person-group person-group-type="author"><name name-style="western"><surname>Wilding</surname><given-names>J PH</given-names></name><name name-style="western"><surname>Batterham</surname><given-names>R L</given-names></name><name name-style="western"><surname>Calanna</surname><given-names>S</given-names></name></person-group><etal/><article-title>Once-weekly semaglutide in adults with overweight or obesity</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>11</issue><fpage>989</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">33567185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2032183</pub-id></mixed-citation></ref><ref id="JR250061ra-84"><label>84</label><mixed-citation publication-type="journal"><collab>STEP 3 Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Wadden</surname><given-names>T A</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>T S</given-names></name><name name-style="western"><surname>Billings</surname><given-names>L K</given-names></name></person-group><etal/><article-title>Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 Randomized Clinical Trial</article-title><source>JAMA</source><year>2021</year><volume>325</volume><issue>14</issue><fpage>1403</fpage><lpage>1413</lpage><pub-id pub-id-type="pmid">33625476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.1831</pub-id><pub-id pub-id-type="pmcid">PMC7905697</pub-id></mixed-citation></ref><ref id="JR250061ra-85"><label>85</label><mixed-citation publication-type="journal"><collab>SAVOR-TIMI 53 Steering Committee and Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Scirica</surname><given-names>B M</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>D L</given-names></name><name name-style="western"><surname>Braunwald</surname><given-names>E</given-names></name></person-group><etal/><article-title>Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>14</issue><fpage>1317</fpage><lpage>1326</lpage><pub-id pub-id-type="pmid">23992601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1307684</pub-id></mixed-citation></ref><ref id="JR250061ra-86"><label>86</label><mixed-citation publication-type="journal"><collab>EXAMINE Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>W B</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>C P</given-names></name><name name-style="western"><surname>Heller</surname><given-names>S R</given-names></name></person-group><etal/><article-title>Alogliptin after acute coronary syndrome in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>14</issue><fpage>1327</fpage><lpage>1335</lpage><pub-id pub-id-type="pmid">23992602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1305889</pub-id></mixed-citation></ref><ref id="JR250061ra-87"><label>87</label><mixed-citation publication-type="journal"><collab>TECOS Study Group </collab><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>J B</given-names></name><name name-style="western"><surname>Bethel</surname><given-names>M A</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>P W</given-names></name></person-group><etal/><article-title>Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><issue>03</issue><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">26052984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1501352</pub-id></mixed-citation></ref><ref id="JR250061ra-88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gantz</surname><given-names>I</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Suryawanshi</surname><given-names>S</given-names></name></person-group><etal/><article-title>A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus</article-title><source>Cardiovasc Diabetol</source><year>2017</year><volume>16</volume><issue>01</issue><fpage>112</fpage><pub-id pub-id-type="pmid">28893244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-017-0593-8</pub-id><pub-id pub-id-type="pmcid">PMC5594521</pub-id></mixed-citation></ref><ref id="JR250061ra-89"><label>89</label><mixed-citation publication-type="journal"><collab>CARMELINA Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Rosenstock</surname><given-names>J</given-names></name><name name-style="western"><surname>Perkovic</surname><given-names>V</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>O E</given-names></name></person-group><etal/><article-title>Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial</article-title><source>JAMA</source><year>2019</year><volume>321</volume><issue>01</issue><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">30418475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.18269</pub-id><pub-id pub-id-type="pmcid">PMC6583576</pub-id></mixed-citation></ref><ref id="JR250061ra-90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrannini</surname><given-names>E</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>S J</given-names></name><name name-style="western"><surname>Salsali</surname><given-names>A</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>List</surname><given-names>J F</given-names></name></person-group><article-title>Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><issue>10</issue><fpage>2217</fpage><lpage>2224</lpage><pub-id pub-id-type="pmid">20566676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc10-0612</pub-id><pub-id pub-id-type="pmcid">PMC2945163</pub-id></mixed-citation></ref><ref id="JR250061ra-91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strojek</surname><given-names>K</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>K H</given-names></name><name name-style="western"><surname>Hruba</surname><given-names>V</given-names></name><name name-style="western"><surname>Elze</surname><given-names>M</given-names></name><name name-style="western"><surname>Langkilde</surname><given-names>A M</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>S</given-names></name></person-group><article-title>Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial</article-title><source>Diabetes Obes Metab</source><year>2011</year><volume>13</volume><issue>10</issue><fpage>928</fpage><lpage>938</lpage><pub-id pub-id-type="pmid">21672123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1463-1326.2011.01434.x</pub-id></mixed-citation></ref><ref id="JR250061ra-92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nauck</surname><given-names>M A</given-names></name><name name-style="western"><surname>Del Prato</surname><given-names>S</given-names></name><name name-style="western"><surname>Meier</surname><given-names>J J</given-names></name></person-group><etal/><article-title>Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial</article-title><source>Diabetes Care</source><year>2011</year><volume>34</volume><issue>09</issue><fpage>2015</fpage><lpage>2022</lpage><pub-id pub-id-type="pmid">21816980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc11-0606</pub-id><pub-id pub-id-type="pmcid">PMC3161265</pub-id></mixed-citation></ref><ref id="JR250061ra-93"><label>93</label><mixed-citation publication-type="journal"><collab>Dapagliflozin 006 Study Group </collab><person-group person-group-type="author"><name name-style="western"><surname>Wilding</surname><given-names>J P</given-names></name><name name-style="western"><surname>Woo</surname><given-names>V</given-names></name><name name-style="western"><surname>Rohwedder</surname><given-names>K</given-names></name><name name-style="western"><surname>Sugg</surname><given-names>J</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>S</given-names></name></person-group><article-title>Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years</article-title><source>Diabetes Obes Metab</source><year>2014</year><volume>16</volume><issue>02</issue><fpage>124</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">23911013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.12187</pub-id></mixed-citation></ref><ref id="JR250061ra-94"><label>94</label><mixed-citation publication-type="journal"><collab>EMPA-REG METSU Trial Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>H&#228;ring</surname><given-names>H U</given-names></name><name name-style="western"><surname>Merker</surname><given-names>L</given-names></name><name name-style="western"><surname>Seewaldt-Becker</surname><given-names>E</given-names></name></person-group><etal/><article-title>Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><issue>11</issue><fpage>3396</fpage><lpage>3404</lpage><pub-id pub-id-type="pmid">23963895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc12-2673</pub-id><pub-id pub-id-type="pmcid">PMC3816918</pub-id></mixed-citation></ref><ref id="JR250061ra-95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenl&#246;f</surname><given-names>K</given-names></name><name name-style="western"><surname>Cefalu</surname><given-names>W T</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K A</given-names></name></person-group><etal/><article-title>Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study</article-title><source>Curr Med Res Opin</source><year>2014</year><volume>30</volume><issue>02</issue><fpage>163</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">24073995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1185/03007995.2013.850066</pub-id></mixed-citation></ref><ref id="JR250061ra-96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilding</surname><given-names>J P</given-names></name><name name-style="western"><surname>Charpentier</surname><given-names>G</given-names></name><name name-style="western"><surname>Hollander</surname><given-names>P</given-names></name></person-group><etal/><article-title>Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial</article-title><source>Int J Clin Pract</source><year>2013</year><volume>67</volume><issue>12</issue><fpage>1267</fpage><lpage>1282</lpage><pub-id pub-id-type="pmid">24118688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijcp.12322</pub-id><pub-id pub-id-type="pmcid">PMC4282288</pub-id></mixed-citation></ref><ref id="JR250061ra-97"><label>97</label><mixed-citation publication-type="journal"><collab>EMPA-REG MONO trial investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Roden</surname><given-names>M</given-names></name><name name-style="western"><surname>Weng</surname><given-names>J</given-names></name><name name-style="western"><surname>Eilbracht</surname><given-names>J</given-names></name></person-group><etal/><article-title>Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2013</year><volume>1</volume><issue>03</issue><fpage>208</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">24622369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(13)70084-6</pub-id></mixed-citation></ref><ref id="JR250061ra-98"><label>98</label><mixed-citation publication-type="journal"><collab>EMPA-REG RENAL trial investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Barnett</surname><given-names>A H</given-names></name><name name-style="western"><surname>Mithal</surname><given-names>A</given-names></name><name name-style="western"><surname>Manassie</surname><given-names>J</given-names></name></person-group><etal/><article-title>Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2014</year><volume>2</volume><issue>05</issue><fpage>369</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">24795251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(13)70208-0</pub-id></mixed-citation></ref><ref id="JR250061ra-99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leiter</surname><given-names>L A</given-names></name><name name-style="western"><surname>Cefalu</surname><given-names>W T</given-names></name><name name-style="western"><surname>de Bruin</surname><given-names>T W</given-names></name><name name-style="western"><surname>Gause-Nilsson</surname><given-names>I</given-names></name><name name-style="western"><surname>Sugg</surname><given-names>J</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>S J</given-names></name></person-group><article-title>Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension</article-title><source>J Am Geriatr Soc</source><year>2014</year><volume>62</volume><issue>07</issue><fpage>1252</fpage><lpage>1262</lpage><pub-id pub-id-type="pmid">24890683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgs.12881</pub-id></mixed-citation></ref><ref id="JR250061ra-100"><label>100</label><mixed-citation publication-type="journal"><collab>EMPA-REG MDI Trial Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Rosenstock</surname><given-names>J</given-names></name><name name-style="western"><surname>Jelaska</surname><given-names>A</given-names></name><name name-style="western"><surname>Frappin</surname><given-names>G</given-names></name></person-group><etal/><article-title>Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes</article-title><source>Diabetes Care</source><year>2014</year><volume>37</volume><issue>07</issue><fpage>1815</fpage><lpage>1823</lpage><pub-id pub-id-type="pmid">24929430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc13-3055</pub-id></mixed-citation></ref><ref id="JR250061ra-101"><label>101</label><mixed-citation publication-type="journal"><collab>EMPA-REG H2H-SU Trial Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Ridderstr&#229;le</surname><given-names>M</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>K R</given-names></name><name name-style="western"><surname>Zeller</surname><given-names>C</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G</given-names></name><name name-style="western"><surname>Woerle</surname><given-names>H J</given-names></name><name name-style="western"><surname>Broedl</surname><given-names>U C</given-names></name></person-group><article-title>Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2014</year><volume>2</volume><issue>09</issue><fpage>691</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">24948511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(14)70120-2</pub-id></mixed-citation></ref><ref id="JR250061ra-102"><label>102</label><mixed-citation publication-type="journal"><collab>DIA3004 Study Group </collab><person-group person-group-type="author"><name name-style="western"><surname>Yale</surname><given-names>J F</given-names></name><name name-style="western"><surname>Bakris</surname><given-names>G</given-names></name><name name-style="western"><surname>Cariou</surname><given-names>B</given-names></name></person-group><etal/><article-title>Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease</article-title><source>Diabetes Obes Metab</source><year>2014</year><volume>16</volume><issue>10</issue><fpage>1016</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">24965700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.12348</pub-id></mixed-citation></ref><ref id="JR250061ra-103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leiter</surname><given-names>L A</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>K H</given-names></name><name name-style="western"><surname>Arias</surname><given-names>P</given-names></name></person-group><etal/><article-title>Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><issue>03</issue><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">25205142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc13-2762</pub-id></mixed-citation></ref><ref id="JR250061ra-104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenstock</surname><given-names>J</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>L</given-names></name><name name-style="western"><surname>Zee</surname><given-names>P</given-names></name></person-group><etal/><article-title>Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><issue>03</issue><fpage>376</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">25352655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc14-1142</pub-id></mixed-citation></ref><ref id="JR250061ra-105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bode</surname><given-names>B</given-names></name><name name-style="western"><surname>Stenl&#246;f</surname><given-names>K</given-names></name><name name-style="western"><surname>Harris</surname><given-names>S</given-names></name></person-group><etal/><article-title>Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes</article-title><source>Diabetes Obes Metab</source><year>2015</year><volume>17</volume><issue>03</issue><fpage>294</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">25495720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.12428</pub-id></mixed-citation></ref><ref id="JR250061ra-106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeFronzo</surname><given-names>R A</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>A</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name></person-group><etal/><article-title>Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><issue>03</issue><fpage>384</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">25583754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc14-2364</pub-id></mixed-citation></ref><ref id="JR250061ra-107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewin</surname><given-names>A</given-names></name><name name-style="western"><surname>DeFronzo</surname><given-names>R A</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name></person-group><etal/><article-title>Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><issue>03</issue><fpage>394</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">25633662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc14-2365</pub-id></mixed-citation></ref><ref id="JR250061ra-108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cefalu</surname><given-names>W T</given-names></name><name name-style="western"><surname>Leiter</surname><given-names>L A</given-names></name><name name-style="western"><surname>de Bruin</surname><given-names>T W</given-names></name><name name-style="western"><surname>Gause-Nilsson</surname><given-names>I</given-names></name><name name-style="western"><surname>Sugg</surname><given-names>J</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>S J</given-names></name></person-group><article-title>Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><issue>07</issue><fpage>1218</fpage><lpage>1227</lpage><pub-id pub-id-type="pmid">25852208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc14-0315</pub-id><pub-id pub-id-type="pmcid">PMC4831907</pub-id></mixed-citation></ref><ref id="JR250061ra-109"><label>109</label><mixed-citation publication-type="journal"><collab>EMPA-REG EXTEND MET investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Merker</surname><given-names>L</given-names></name><name name-style="western"><surname>H&#228;ring</surname><given-names>H U</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>A V</given-names></name></person-group><etal/><article-title>Empagliflozin as add-on to metformin in people with Type 2 diabetes</article-title><source>Diabet Med</source><year>2015</year><volume>32</volume><issue>12</issue><fpage>1555</fpage><lpage>1567</lpage><pub-id pub-id-type="pmid">26031566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dme.12814</pub-id></mixed-citation></ref><ref id="JR250061ra-110"><label>110</label><mixed-citation publication-type="journal"><collab>EMPA-REG EXTEND&#8482; PIO investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Kovacs</surname><given-names>C S</given-names></name><name name-style="western"><surname>Seshiah</surname><given-names>V</given-names></name><name name-style="western"><surname>Merker</surname><given-names>L</given-names></name></person-group><etal/><article-title>Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus</article-title><source>Clin Ther</source><year>2015</year><volume>37</volume><issue>08</issue><fpage>1773</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">26138864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2015.05.511</pub-id></mixed-citation></ref><ref id="JR250061ra-111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenstock</surname><given-names>J</given-names></name><name name-style="western"><surname>Chuck</surname><given-names>L</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Ortiz</surname><given-names>M</given-names></name></person-group><etal/><article-title>Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-na&#239;ve type 2 diabetes</article-title><source>Diabetes Care</source><year>2016</year><volume>39</volume><issue>03</issue><fpage>353</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">26786577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc15-1736</pub-id></mixed-citation></ref><ref id="JR250061ra-112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terra</surname><given-names>S G</given-names></name><name name-style="western"><surname>Focht</surname><given-names>K</given-names></name><name name-style="western"><surname>Davies</surname><given-names>M</given-names></name></person-group><etal/><article-title>Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone</article-title><source>Diabetes Obes Metab</source><year>2017</year><volume>19</volume><issue>05</issue><fpage>721</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">28116776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.12888</pub-id></mixed-citation></ref><ref id="JR250061ra-113"><label>113</label><mixed-citation publication-type="journal"><collab>CANVAS Program Collaborative Group </collab><person-group person-group-type="author"><name name-style="western"><surname>Neal</surname><given-names>B</given-names></name><name name-style="western"><surname>Perkovic</surname><given-names>V</given-names></name><name name-style="western"><surname>Mahaffey</surname><given-names>K W</given-names></name></person-group><etal/><article-title>Canagliflozin and cardiovascular and renal events in type 2 diabetes</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><issue>07</issue><fpage>644</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">28605608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1611925</pub-id></mixed-citation></ref><ref id="JR250061ra-114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pratley</surname><given-names>R E</given-names></name><name name-style="western"><surname>Eldor</surname><given-names>R</given-names></name><name name-style="western"><surname>Raji</surname><given-names>A</given-names></name></person-group><etal/><article-title>Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial</article-title><source>Diabetes Obes Metab</source><year>2018</year><volume>20</volume><issue>05</issue><fpage>1111</fpage><lpage>1120</lpage><pub-id pub-id-type="pmid">29266675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.13194</pub-id><pub-id pub-id-type="pmcid">PMC5947297</pub-id></mixed-citation></ref><ref id="JR250061ra-115"><label>115</label><mixed-citation publication-type="journal"><collab>DECLARE&#8211;TIMI 58 Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Wiviott</surname><given-names>S D</given-names></name><name name-style="western"><surname>Raz</surname><given-names>I</given-names></name><name name-style="western"><surname>Bonaca</surname><given-names>M P</given-names></name></person-group><etal/><article-title>Dapagliflozin and cardiovascular outcomes in type 2 diabetes</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><issue>04</issue><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">30415602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1812389</pub-id></mixed-citation></ref><ref id="JR250061ra-116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallo</surname><given-names>S</given-names></name><name name-style="western"><surname>Charbonnel</surname><given-names>B</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>A</given-names></name></person-group><etal/><article-title>Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial</article-title><source>Diabetes Obes Metab</source><year>2019</year><volume>21</volume><issue>04</issue><fpage>1027</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">30614616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.13631</pub-id><pub-id pub-id-type="pmcid">PMC6593724</pub-id></mixed-citation></ref><ref id="JR250061ra-117"><label>117</label><mixed-citation publication-type="journal"><collab>CREDENCE Trial Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Perkovic</surname><given-names>V</given-names></name><name name-style="western"><surname>Jardine</surname><given-names>M J</given-names></name><name name-style="western"><surname>Neal</surname><given-names>B</given-names></name></person-group><etal/><article-title>Canagliflozin and renal outcomes in type 2 diabetes and nephropathy</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><issue>24</issue><fpage>2295</fpage><lpage>2306</lpage><pub-id pub-id-type="pmid">30990260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1811744</pub-id></mixed-citation></ref><ref id="JR250061ra-118"><label>118</label><mixed-citation publication-type="journal"><collab>EMPEROR-Reduced Trial Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Packer</surname><given-names>M</given-names></name><name name-style="western"><surname>Anker</surname><given-names>S D</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J</given-names></name></person-group><etal/><article-title>Cardiovascular and renal outcomes with empagliflozin in heart failure</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>15</issue><fpage>1413</fpage><lpage>1424</lpage><pub-id pub-id-type="pmid">32865377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2022190</pub-id></mixed-citation></ref><ref id="JR250061ra-119"><label>119</label><mixed-citation publication-type="journal"><collab>VERTIS CV Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Cannon</surname><given-names>C P</given-names></name><name name-style="western"><surname>Pratley</surname><given-names>R</given-names></name><name name-style="western"><surname>Dagogo-Jack</surname><given-names>S</given-names></name></person-group><etal/><article-title>Cardiovascular outcomes with ertugliflozin in type 2 diabetes</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>15</issue><fpage>1425</fpage><lpage>1435</lpage><pub-id pub-id-type="pmid">32966714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2004967</pub-id></mixed-citation></ref><ref id="JR250061ra-120"><label>120</label><mixed-citation publication-type="journal"><collab>SCORED Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>D L</given-names></name><name name-style="western"><surname>Szarek</surname><given-names>M</given-names></name><name name-style="western"><surname>Pitt</surname><given-names>B</given-names></name></person-group><etal/><article-title>Sotagliflozin in patients with diabetes and chronic kidney disease</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>02</issue><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">33200891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2030186</pub-id></mixed-citation></ref><ref id="JR250061ra-121"><label>121</label><mixed-citation publication-type="journal"><collab>SOLOIST-WHF Trial Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>D L</given-names></name><name name-style="western"><surname>Szarek</surname><given-names>M</given-names></name><name name-style="western"><surname>Steg</surname><given-names>P G</given-names></name></person-group><etal/><article-title>Sotagliflozin in patients with diabetes and recent worsening heart failure</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>02</issue><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">33200892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2030183</pub-id></mixed-citation></ref><ref id="JR250061ra-122"><label>122</label><mixed-citation publication-type="journal"><collab>EMPEROR-Preserved Trial Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Anker</surname><given-names>S D</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J</given-names></name><name name-style="western"><surname>Filippatos</surname><given-names>G</given-names></name></person-group><etal/><article-title>Empagliflozin in heart failure with a preserved ejection fraction</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><issue>16</issue><fpage>1451</fpage><lpage>1461</lpage><pub-id pub-id-type="pmid">34449189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2107038</pub-id></mixed-citation></ref><ref id="JR250061ra-123"><label>123</label><mixed-citation publication-type="journal"><collab>DELIVER Trial Committees and Investigators </collab><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>S D</given-names></name><name name-style="western"><surname>McMurray</surname><given-names>J JV</given-names></name><name name-style="western"><surname>Claggett</surname><given-names>B</given-names></name></person-group><etal/><article-title>Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction</article-title><source>N Engl J Med</source><year>2022</year><volume>387</volume><issue>12</issue><fpage>1089</fpage><lpage>1098</lpage><pub-id pub-id-type="pmid">36027570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2206286</pub-id></mixed-citation></ref><ref id="JR250061ra-124"><label>124</label><mixed-citation publication-type="journal"><collab>The EMPA-KIDNEY Collaborative Group </collab><person-group person-group-type="author"><name name-style="western"><surname>Herrington</surname><given-names>W G</given-names></name><name name-style="western"><surname>Staplin</surname><given-names>N</given-names></name><name name-style="western"><surname>Wanner</surname><given-names>C</given-names></name></person-group><etal/><article-title>Empagliflozin in patients with chronic kidney disease</article-title><source>N Engl J Med</source><year>2023</year><volume>388</volume><issue>02</issue><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">36331190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2204233</pub-id><pub-id pub-id-type="pmcid">PMC7614055</pub-id></mixed-citation></ref><ref id="JR250061ra-125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenstock</surname><given-names>J</given-names></name><name name-style="western"><surname>Frias</surname><given-names>J</given-names></name><name name-style="western"><surname>P&#225;ll</surname><given-names>D</given-names></name></person-group><etal/><article-title>Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)</article-title><source>Diabetes Obes Metab</source><year>2018</year><volume>20</volume><issue>03</issue><fpage>520</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">28857451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.13103</pub-id></mixed-citation></ref><ref id="JR250061ra-126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dagogo-Jack</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Eldor</surname><given-names>R</given-names></name></person-group><etal/><article-title>Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study</article-title><source>Diabetes Obes Metab</source><year>2018</year><volume>20</volume><issue>03</issue><fpage>530</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">28921862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.13116</pub-id><pub-id pub-id-type="pmcid">PMC5836931</pub-id></mixed-citation></ref><ref id="JR250061ra-127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grunberger</surname><given-names>G</given-names></name><name name-style="western"><surname>Camp</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J</given-names></name></person-group><etal/><article-title>Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: The VERTIS RENAL Randomized Study</article-title><source>Diabetes Ther</source><year>2018</year><volume>9</volume><issue>01</issue><fpage>49</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">29159457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13300-017-0337-5</pub-id><pub-id pub-id-type="pmcid">PMC5801223</pub-id></mixed-citation></ref><ref id="JR250061ra-128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hollander</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Hill</surname><given-names>J</given-names></name></person-group><etal/><article-title>Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU Randomized Study</article-title><source>Diabetes Ther</source><year>2018</year><volume>9</volume><issue>01</issue><fpage>193</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">29282633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13300-017-0354-4</pub-id><pub-id pub-id-type="pmcid">PMC5801240</pub-id></mixed-citation></ref><ref id="JR250061ra-129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>S</given-names></name><name name-style="western"><surname>Krumins</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name></person-group><etal/><article-title>Ertugliflozin and s: The VERTIS SITA Randomized Study</article-title><source>Diabetes Ther</source><year>2018</year><volume>9</volume><issue>01</issue><fpage>253</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">29313282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13300-017-0358-0</pub-id><pub-id pub-id-type="pmcid">PMC5801244</pub-id></mixed-citation></ref><ref id="JR250061ra-130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulze</surname><given-names>P C</given-names></name><name name-style="western"><surname>Bogoviku</surname><given-names>J</given-names></name><name name-style="western"><surname>Westphal</surname><given-names>J</given-names></name></person-group><etal/><article-title>Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)</article-title><source>Circulation</source><year>2022</year><volume>146</volume><issue>04</issue><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">35766022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.122.059038</pub-id></mixed-citation></ref><ref id="JR250061ra-131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutsey</surname><given-names>P L</given-names></name><name name-style="western"><surname>Zakai</surname><given-names>N A</given-names></name></person-group><article-title>Epidemiology and prevention of venous thromboembolism</article-title><source>Nat Rev Cardiol</source><year>2023</year><volume>20</volume><issue>04</issue><fpage>248</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">36258120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-022-00787-6</pub-id><pub-id pub-id-type="pmcid">PMC9579604</pub-id></mixed-citation></ref><ref id="JR250061ra-132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sendor</surname><given-names>R</given-names></name><name name-style="western"><surname>St&#252;rmer</surname><given-names>T</given-names></name></person-group><article-title>Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2022</year><volume>31</volume><issue>03</issue><fpage>261</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">35019190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pds.5407</pub-id><pub-id pub-id-type="pmcid">PMC9121653</pub-id></mixed-citation></ref><ref id="JR250061ra-133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chien</surname><given-names>C T</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S C</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S C</given-names></name></person-group><etal/><article-title>Glucagon-like peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure in chronic kidney disease</article-title><source>Thromb Haemost</source><year>2014</year><volume>112</volume><issue>05</issue><fpage>1051</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">25030617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1160/TH14-03-0258</pub-id></mixed-citation></ref><ref id="JR250061ra-134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steven</surname><given-names>S</given-names></name><name name-style="western"><surname>Jurk</surname><given-names>K</given-names></name><name name-style="western"><surname>Kopp</surname><given-names>M</given-names></name></person-group><etal/><article-title>Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice</article-title><source>Br J Pharmacol</source><year>2017</year><volume>174</volume><issue>12</issue><fpage>1620</fpage><lpage>1632</lpage><pub-id pub-id-type="pmid">27435156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.13549</pub-id><pub-id pub-id-type="pmcid">PMC5446582</pub-id></mixed-citation></ref><ref id="JR250061ra-135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evlakhov</surname><given-names>V I</given-names></name><name name-style="western"><surname>Poyasov</surname><given-names>I Z</given-names></name><name name-style="western"><surname>Berezina</surname><given-names>T P</given-names></name></person-group><article-title>Changes of pulmonary microhemodynamics in experimental pulmonary thromboembolism after pretreatment with K-channel activators</article-title><source>Bull Exp Biol Med</source><year>2022</year><volume>173</volume><issue>03</issue><fpage>302</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">35844023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10517-022-05538-8</pub-id></mixed-citation></ref><ref id="JR250061ra-136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sechterberger</surname><given-names>M K</given-names></name><name name-style="western"><surname>Hermanides</surname><given-names>J</given-names></name><name name-style="western"><surname>Poolman</surname><given-names>R W</given-names></name></person-group><etal/><article-title>Lowering blood glucose during hip surgery does not influence coagulation activation</article-title><source>BBA Clin</source><year>2015</year><volume>3</volume><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">26675337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbacli.2015.03.001</pub-id><pub-id pub-id-type="pmcid">PMC4661563</pub-id></mixed-citation></ref><ref id="JR250061ra-137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nylander</surname><given-names>M</given-names></name><name name-style="western"><surname>Fr&#248;ssing</surname><given-names>S</given-names></name><name name-style="western"><surname>Kistorp</surname><given-names>C</given-names></name><name name-style="western"><surname>Faber</surname><given-names>J</given-names></name><name name-style="western"><surname>Skouby</surname><given-names>S O</given-names></name></person-group><article-title>Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential</article-title><source>Endocr Connect</source><year>2017</year><volume>6</volume><issue>02</issue><fpage>89</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">28119323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/EC-16-0113</pub-id><pub-id pub-id-type="pmcid">PMC5424770</pub-id></mixed-citation></ref><ref id="JR250061ra-138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iorio</surname><given-names>A</given-names></name><name name-style="western"><surname>Kearon</surname><given-names>C</given-names></name><name name-style="western"><surname>Filippucci</surname><given-names>E</given-names></name></person-group><etal/><article-title>Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review</article-title><source>Arch Intern Med</source><year>2010</year><volume>170</volume><issue>19</issue><fpage>1710</fpage><lpage>1716</lpage><pub-id pub-id-type="pmid">20975016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archinternmed.2010.367</pub-id></mixed-citation></ref><ref id="JR250061ra-139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soon</surname><given-names>D</given-names></name><name name-style="western"><surname>Kothare</surname><given-names>P A</given-names></name><name name-style="western"><surname>Linnebjerg</surname><given-names>H</given-names></name></person-group><etal/><article-title>Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men</article-title><source>J Clin Pharmacol</source><year>2006</year><volume>46</volume><issue>10</issue><fpage>1179</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">16988207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270006291622</pub-id></mixed-citation></ref><ref id="JR250061ra-140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasichayanula</surname><given-names>S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name></person-group><etal/><article-title>Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin</article-title><source>Adv Ther</source><year>2012</year><volume>29</volume><issue>02</issue><fpage>163</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">22271159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-011-0098-x</pub-id></mixed-citation></ref><ref id="JR250061ra-141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macha</surname><given-names>S</given-names></name><name name-style="western"><surname>Rose</surname><given-names>P</given-names></name><name name-style="western"><surname>Mattheus</surname><given-names>M</given-names></name><name name-style="western"><surname>Pinnetti</surname><given-names>S</given-names></name><name name-style="western"><surname>Woerle</surname><given-names>H J</given-names></name></person-group><article-title>Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers</article-title><source>Diabetes Obes Metab</source><year>2013</year><volume>15</volume><issue>04</issue><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">23094794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.12028</pub-id></mixed-citation></ref><ref id="OR250061ra-142"><label>142</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>S&#228;ll</surname><given-names>C</given-names></name><name name-style="western"><surname>Alifrangis</surname><given-names>L</given-names></name><name name-style="western"><surname>Dahl</surname><given-names>K</given-names></name><name name-style="western"><surname>Friedrichsen</surname><given-names>M H</given-names></name><name name-style="western"><surname>Nyg&#229;rd</surname><given-names>S B</given-names></name><name name-style="western"><surname>Kristensen</surname><given-names>K</given-names></name></person-group><article-title>In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic</article-title>Drug Metab Dispos 2022;50(08):DMD-AR-2022-000865<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.122.000865</pub-id><pub-id pub-id-type="pmid">35680133</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>